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A B S T R A C T
Background
Buruli ulcer is a necrotizing cutaneous infection caused by infection withMycobacterium ulcerans bacteria that occurs mainly in tropical
and subtropical regions. The infection progresses from nodules under the skin to deep ulcers, often on the upper and lower limbs or
on the face. If left undiagnosed and untreated, it can lead to lifelong disfigurement and disabilities. It is often treated with drugs and
surgery.
Objectives
To summarize the evidence of drug treatments for treating Buruli ulcer.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register; the Cochrane Central Register of Controlled Trials (CEN-
TRAL), published in the Cochrane Library; MEDLINE ( PubMed); Embase ( Ovid); and LILACS ( Latin American and Caribbean
Health Sciences Literature; BIREME).We also searched theUSNational Institutes of HealthOngoing Trials Register ( clinicaltrials.gov)
and the World Health Organization ( WHO) International Clinical Trials Registry Platform ( ICTRP) ( www.who.int/ictrp/search/
en/). All searches were run up to 19 December 2017. We also checked the reference lists of articles identified by the literature search,
and contacted leading researchers in this topic area to identify any unpublished data.
Selection criteria
We included randomized controlled trials (RCTs) that compared antibiotic therapy to placebo or alternative therapy such as surgery,
or that compared different antibiotic regimens. We also included prospective observational studies that evaluated different antibiotic
regimens with or without surgery.
Data collection and analysis
Two review authors independently applied the inclusion criteria, extracted the data, and assessed methodological quality. We calculated
the risk ratio (RR) for dichotomous data with 95% confidence intervals (CI). We assessed the certainty of the evidence using the
GRADE approach.
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Main results
We included a total of 18 studies: five RCTs involving a total of 319 participants, ranging from 12 participants to 151 participants,
and 13 prospective observational studies, with 1665 participants. Studies evaluated various drugs usually in addition to surgery, and
were carried out across eight countries in areas with high Buruli ulcer endemicity in West Africa and Australia. Only one RCT reported
adequate methods to minimize bias. Regarding monotherapy, one RCT and one observational study evaluated clofazimine, and one
RCT evaluated sulfamethoxazole/trimethoprim. All three studies had small sample sizes, and no treatment effect was demonstrated.
The remaining studies examined combination therapy.
Rifampicin combined with streptomycin
We found one RCT and six observational studies which evaluated rifampicin combined with streptomycin for different lengths of
treatment (2, 4, 8, or 12 weeks) (941 participants). The RCT did not demonstrate a difference between the drugs added to surgery
compared with surgery alone for recurrence at 12 months, but was underpowered (RR 0.12, 95% CI 0.01 to 2.51; 21 participants;
very low-certainty evidence).
An additional five single-arm observational studies with 828 participants using this regimen for eight weeks with surgery (given to
either all participants or to a select group) reported healing rates ranging from 84.5% to 100%, assessed between six weeks and one year.
Four observational studies reported healing rates for participants who received the regimen alone without surgery, reporting healing
rates ranging from 48% to 95% assessed between eight weeks and one year.
Rifampicin combined with clarithromycin
Two observational studies administered combined rifampicin and clarithromycin. One study evaluated the regimen alone (no surgery)
for eight weeks and reported a healing rate of 50% at 12 months (30 participants). Another study evaluated the regimen administered
for various durations (as determined by the clinicians, durations unspecified) with surgery and reported a healing rate of 100% at 12
months (21 participants).
Rifampicin with streptomycin initially, changing to rifampicin with clarithromycin in consolidation phase
One RCT evaluated this regimen (four weeks in each phase) against continuing with rifampicin and streptomycin in the consolidation
phase (total eight weeks). All included participants had small lesions, and healing rates were above 90% in both groups without surgery
(healing rate at 12 months RR 0.94, 95% CI 0.87 to 1.03; 151 participants; low-certainty evidence). One single-arm observational
study evaluating the substitution of streptomycin with clarithromycin in the consolidation phase (6 weeks, total 8 weeks) without
surgery given to a select group showed a healing rate of 98% at 12 months (41 participants).
Novel combination therapy
Two large prospective studies in Australia evaluated some novel regimens. One study evaluating rifampicin combined with either
ciprofloxacin, clarithromycin, or moxifloxacin without surgery reported a healing rate of 76.5% at 12 months (132 participants).
Another study evaluating combinations of two to three drugs from rifampicin, ciprofloxacin, clarithromycin, ethambutol, moxifloxacin,
or amikacin with surgery reported a healing rate of 100% (90 participants).
Adverse effects were reported in only three RCTs (158 participants) and eight prospective observational studies (878 participants), and
were consistent with what is already known about the adverse effect profile of these drugs. Paradoxical reactions (clinical deterioration
after treatment caused by enhanced immune response to M ulcerans) were evaluated in six prospective observational studies (822
participants), and the incidence of paradoxical reactions ranged from 1.9% to 26%.
Authors’ conclusions
While the antibiotic combination treatments evaluated appear to be effective, we found insufficient evidence showing that any particular
drug is more effective than another. How different sizes, lesions, and stages of the disease may contribute to healing and which kind
of lesions are in need of surgery are unclear based on the included studies. Guideline development needs to consider these factors in
designing practical treatment regimens. Forthcoming trials using clarithromycin with rifampicin and other trials of new regimens that
also address these factors will help to identify the best regimens.
P L A I N L A N G U A G E S U M M A R Y
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What was the aim of this review?
The aim of this Cochrane Review was to summarize the evidence for drug treatments for Buruli ulcer.
Key messages
Antibiotics are an important component of treatment of Buruli ulcers, but there is no evidence to suggest that any particular drug is
more effective than another.
What was studied in the review?
Buruli ulcer is a disease caused by mycobacterium (tuberculosis and leprosy are other types of diseases caused by mycobacterium),
which results in lumps in the skin and deep ulcers, often on the arms or the face. When diagnosed late, those affected may be left with
lifelong disfigurements and disabilities. The disease is most prevalent in West Africa, but it is also found in non-tropical areas including
Australia and Japan. It is often treated with drugs and surgery. This review compared different drug treatments for Buruli ulcer.
What are the main results of the review?
We included 18 studies from eight countries in West Africa and Australia (1984 participants). Antibiotic combination treatments
evaluated appear to be effective, but the evidence is insufficient to show that any particular drug is more effective than another.
Testing treatments in Buruli ulcer is challenging as different sizes, lesions, and stages of the disease contribute to healing rates. Surgery
also plays an important role in treating Buruli ulcer, and consequently the independent effect of drugs is difficult to assess. Trials of
new regimens that also address these factors will help to identify the best regimens.
How up-to-date is this review?
We searched for studies published up to 19 December 2017.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Rifampicin combined with streptomycin compared with surgery alone for Buruli ulcer
Patient or population: people with Buruli ulcer, non-ulcerated lesions measuring less than 10 cm in diameter, aged 15 years or older
Settings: Ghana
Intervention: rif ampicin combined with streptomycin
Comparison: surgery alone
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Surgery alone Surgery plus rifampicin
combined with strepto-
mycin
Recurrence,
12 months
20 per 100 2.4 per 100
(< 1 to 50)
RR 0.12 (0.01 to 2.51) 21 part icipants
(1 trial)
⊕©©©
VERY LOWa,b
due to risk of bias and
imprecision
We do not know if the
treatment reduces re-
currence.
* The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95%CI) is based on the
assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
Abbreviations: CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.
aDowngraded by 1 for risk of bias: study small and not concealed.
bDowngraded by 2 for imprecision: very few events and wide CIs.
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B A C K G R O U N D
Buruli ulcer is a necrotizing cutaneous infection caused by infec-
tionwithMycobacterium ulcerans bacteria, which is categorized as a
non-tuberculous mycobacterium. It is an emerging disease first de-
scribed byMacCallum 1948 in six Australian patients. The disease
was named after Buruli County in Uganda, where a large number
of cases were reported in the 1960s (Clancey 1961; Uganda Buruli
Group 1970). Since then, the number of Buruli ulcer cases has
gradually increased (Yotsu 2015). In spite of this, the disease is still
poorly understood, especially its transmission mode. Several stud-
ies have demonstrated that the infection is linked to aquatic envi-
ronments (Lunn 1965; Bradley 1971; Marsollier 2002; Eddyani
2004; Johnson 2005b). However, the natural reservoir and mode
of transmission of the infection remain a mystery and may differ
between endemic foci worldwide (Merritt 2010).
Currently, over 33 countries worldwide report cases of Buruli ul-
cer, mainly in people living in tropical and subtropical regions
(WHO 2013). About 2000 to 5000 new cases are reported an-
nually, mostly in countries in West and Central Africa (WHO
2013). Most people who are infected in these countries are chil-
dren aged under 15 years, living in remote rural areas with limited
access to health facilities (Marston 1995; Asiedu 1998; Phanzu
2006; Wansbrough-Jones 2006). Other important foci include
Australia (Boyd 2012; Tai 2018), French Guiana (Couppié 2015),
Papua New Guinea (Igo 1988; Joseph 2003), and more recently,
Japan (Yotsu 2012). In addition, a number of cases have been
reported in international travellers from non-endemic areas, in-
cluding North America and European countries (van Oye 1950;
Farber 1967; Bär 1998; Semret 1999; Faber 2000; Evans 2003;
Ezzedine 2009). Nevertheless, awareness and knowledge of the
disease among health practitioners and the community are still
lacking, hence the possibility of hidden unreported cases (WHO
2013). In endemic countries, poor health infrastructure and geo-
graphical challenges also contribute to the underreporting of cases
(WHO 2013). If left undiagnosed and untreated, the disease can
lead to lifelongdisfigurement anddisabilities, which impact greatly
on the lives of those affected, especially in resource-poor condi-
tions where most of these people reside.
Description of the condition
The subcutaneous tissue is the primary site of infection by M
ulcerans (van der Werf 1999). The bacteria produce mycolac-
tone, an immunomodulatory macrolide toxin, which is the main
pathogenic factor of the disease. This toxin induces tissue necrosis,
particularly in subcutaneous fat (van derWerf 2003). Initially, the
disease presents as a nodule, papule, plaque (firm, painless, and
raised lesion, which is larger than a papule), or oedema, which
when left alone eventually breaks open the skin and forms an ul-
cer. A typical ulcer usually has necrotic slough, undermined edges,
and is often painless (unless complicated with a secondary infec-
tion) (van der Werf 1999). M ulcerans infection often affects the
upper and lower limbs and the face, as these are exposed body
areas. It can progress sideways to become a larger lesion involving
the joints, as well as deeper into the tissue and cause osteomyelitis
in some cases. However, it is rare for the infection to disseminate
systemically and cause death (Sizaire 2006). If death occurs, it is
usually related to sepsis from a secondary infection or tetanus (van
der Werf 1999).
The World Health Organization (WHO) has classified Burui ul-
cer lesions into three groups according to important clinical fea-
tures and size, with implications for their management (WHO
2012). Category I is a small, early lesion less than 5 cm in diame-
ter; category II is a lesion of 5 to 15 cm in diameter; and category
III is a lesion more than 15 cm in diameter, multiple lesions, or
lesion(s) at a critical site (eye, breast, genitalia) and osteomyeli-
tis (WHO 2012). Some people experience spontaneous healing
during the course of the disease, but the mechanism for this is
unclear (Johnson 2005a; Gordon 2011). In severe cases, lifelong
sequelae may develop. Vincent 2014a reported that among their
1043 laboratory-confirmed cases of Buruli ulcers in Benin, 229
people (22%) developed permanent functional impairment one
year after their treatment.
The association between Buruli ulcer and HIV/AIDS is not yet
clear; there have been some reports on the possible increased rate of
infection and severity in those with HIV/AIDS (Vincent 2014b;
Tuffour 2015).
Diagnosis
Buruli ulcer possesses characteristic clinical features, and hence
clinical diagnosis is possible to a certain extent in endemic ar-
eas. However, for definitive diagnosis, laboratory microbiologi-
cal methods are required, including Ziehl-Neelsen (ZN) staining
for detecting acid-fast bacilli (AFB), in vitro culture, polymerase
chain reaction (PCR) assay targeting genomic region IS2404, and
histopathology. Findings from at least one of these laboratory mi-
crobiological methods should be suggestive of Buruli ulcer to con-
firm diagnosis (WHO 2014). Samples can be obtained by fine-
needle aspiration from a non-ulcerative lesion, and purulent dis-
charge fluid or swab from the undermined wound edge of an ul-
cerative lesion. Skin biopsy is a reliable sample source, but this
can only be performed with adequate skills, tools, and hygienic
environment, which may be limited in places where Buruli ulcer
is endemic. TheWHO is currently promoting PCR confirmation
for at least 70% of all reported cases of Buruli ulcer (WHO 2014).
Description of the intervention
Since the first description of the disease in 1948, the standard
treatment for Buruli ulcers was extensive surgical debridement of
affected skin and surrounding tissue, with or without subsequent
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skin grafting (Darie 1994; van der Werf 2003). However, surgical
treatment alone was insufficient to eradicate all the M ulcerans
bacteria, and recurrence was common. Although the recurrence
rate varied between studies, it was reported to be from 6% to
32% (Amofah 1998; Kanga 2003; Debacker 2005; Kibadi 2006;
O’Brien 2013a). Moreover, surgery is available only to a small
fraction of the population in the most affected areas of low- and
middle-income countries due to limited hospital capacities, and
difficulties relating to accessibility and cost (WHO 2004). Lesion
site is another challenge. If the ulcer involves the face, joints, or
other important body parts, which is not a rare occurrence in
people with Buruli ulcer, surgical excision may cause disfiguring
or disabling consequences (Sizaire 2006). For these reasons, there
has been a continuous exploration for other medical approaches
that can effectively cure Buruli ulcer, including topical treatments
using nitrogen oxide (Phillips 2004a; Phillips 2004b), phenytoin
powder (Klutse 2003), local heat treatment (Meyers 1974; Krieg
1979; Junghanss 2009; Vogel 2016), hyperbaric oxygen therapy
(Krieg 1975; Krieg 1979), and antibiotic treatments (WHO 2004;
WHO 2012; WHO 2017).
Several trials of different antibiotic treatments have been con-
ducted, including clofazimine and sulfamethoxazole/trimetho-
prim (Revill 1973; Fehr 1994), but results of these monothera-
pies were disappointing. Rifampicin, when used alone, caused the
development of a rifampicin-resistant M ulcerans strain in a mice
model, suggesting that it should never be used as monotherapy in
people, as in people with tuberculosis (TB) or leprosy (Marsollier
2003). In 2004, based on in vitro findings and pilot clinical stud-
ies, the WHO introduced a combination of rifampicin (10 mg/
kg orally once daily) and streptomycin (15 mg/kg intramuscularly
once daily) for eight weeks (critical base drugs in TB) as a first-
line therapy for people with Buruli ulcer (WHO 2004), which
has greatly simplified the treatment and delivery of care for those
affected. Nevertheless, surgical treatment adjunctive to antibiotics
still plays an important role in Buruli ulcer management, espe-
cially for people with severe, large ulcers. TheWHO recommends
surgical intervention for category III cases and some category II
cases, following careful assessment of the efficacy of the antibiotic
treatment. In Buruli ulcer, surgical debridement is performed ex-
tensively with a wide margin, as mycolactone exists in the subcu-
taneous fat tissue beyond the wound edges.
Despite antibiotic treatment being effective to an extent, some
concerns remain with the current recommended regimen. Strep-
tomycin requires intramuscular injection, which is invasive, there-
fore patient acceptance and adherence are affected. It is also op-
erationally demanding and of limited availability to people living
in remote areas where Buruli ulcer is most endemic, especially ru-
ral Africa. Additionally, in these areas, administration of drugs by
injection carries the risk of HIV transmission. Potential adverse
effects from streptomycin, including ototoxicity and nephrotoxic-
ity, are another concern. There is also concern about encouraging
the development of multidrug-resistant TB, as both rifampicin
and streptomycin are also effective antituberculosis drugs. Active
TB would need to be confidently ruled out before treatment, and
considering that this judgement may not always be completely
accurate, there may be substantial consequences for the future of
TB treatment. The search for a fully orally administered treatment
regimen to replace rifampicin and streptomycin combination for
the treatment of Buruli ulcer is thus ongoing. Several options have
already been explored as replacements for the curative rifampicin
and streptomycin combination, including: rifampicin and dap-
sone (Espey 2002), rifampicin and clarithromycin (BURULICO
Study 2010; Chauty 2011; Phillips 2014a; Friedman 2016), ri-
fampicin and ciprofloxacin (O’Brien 2012; Friedman 2016), and
rifampicin, levofloxacin, and clarithromycin (Sugawara 2015).
To date, evaluating the efficacy of treatments for Buruli ulcer has
been challenging for several clinical and biological reasons. Firstly,
there have been cases in which deterioration was observed dur-
ing the course of treatment, which are now defined as paradoxi-
cal reactions. This phenomenon is now understood to be the re-
sult of antibiotic suppression of mycolactone synthesis, leading
to the reversal of host immune response toM ulcerans (Nienhuis
2012). Paradoxical reactions may occur at the same site as the ini-
tial lesion, or at other sites. When it is at the same site, it is es-
pecially difficult to differentiate paradoxical reactions from recur-
rences; this identification largely influences the clinical decision.
The WHO defines recurrences as new and culture-confirmed le-
sions occurring more than three months after completion of an-
tibiotic treatment (WHO 2012). However, the two conditions
cannot be fully differentiated based on this definition alone. Since
paradoxical reactions have only recently been documented, some
past data on recurrences may have mistakenly included paradoxi-
cal reactions. Secondly, microbiological cure and clinical cure are
not always the same. In other words, even though M ulcerans was
successfully eliminated from the lesion site with antibiotic treat-
ment (microbiological cure), this does not correspond to clini-
cal cure if the patient has already manifested an ulcer. Moreover,
in such ulcerated cases, methods used in wound care would also
modify the healing process; this is another challenge in correctly
evaluating antimicrobial treatment efficacy in people with Buruli
ulcer. Selection of wound care methods is often dependent upon
daily practice and resource availability. Velding 2014 documented
that there was a wide diversity in local wound care methods prac-
ticed by health practitioners/healthcare givers inGhana andBenin.
Due to these atypical clinical features and medical practices re-
lated to the disease, it has been difficult to develop a clear case
definition for cure. Many studies evaluating treatment efficacy in
Buruli ulcer disease have used complete epithelialization, Chauty
2007; Sugawara 2015, or reduction in wound size, Etuaful 2005;
BURULICO Study 2010; Sugawara 2015, as their definition of
cure (clinical cure), while a few studies have also used microbio-
logical cure as their case definition of cure, employing laboratory
methods (Etuaful 2005; Sarfo 2010).
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How the intervention might work
As Buruli ulcer is a mycobacterial disease and with growing ex-
perience in its management, antibiotic drugs are now an essential
part of its treatment (WHO 2012; Yotsu 2015). After the intro-
duction of antibiotic drugs for the treatment of Buruli ulcer by
theWHO in 2004, recurrence rates reportedly decreased substan-
tially to 0% to 2%, and the need for surgical intervention has di-
minished (Chauty 2007; BURULICO Study 2010; Sarfo 2010).
With this simplified treatment and delivery of care, the quality
of life of patients has increased not only during treatment, but
also after treatment as use of antibiotic drugs has played a role in
decreasing the number of those affected by the disease who are left
with disabilities and disfigurements (Klis 2014c). In West Africa,
where over 40% of those affected are children under 15 years of
age, better treatment further provides better opportunity for edu-
cation, and thus a better future (Agbenorku 2011; WHO 2012).
The use of antibiotic drugs has also decreased the socioeconomic
impact on families, as the cost of treatment of surgeries and hospi-
talization is far beyond the means of those most severely affected
(Asiedu 1998; Grietens 2008; Agbenorku 2011).
Why it is important to do this review
No systematic review of the literature on Buruli ulcer has previ-
ously been performed. A review of the efficacy of daily adminis-
tration of rifampicin and streptomycin in the treatment of early-
stage Buruli ulcer including data from2005 to 2012was published
in 2013 (Vouking 2013). In that review, evidence of diagnostic
accuracy and ascertainment of cure was not clear. Also, the review
did not include treatment modalities other than rifampicin and
streptomycin. In this Cochrane Review, we aimed to assess the
effects of antibiotic treatment with or without surgical interven-
tion (debridement, skin grafting, etc.) for people with Buruli ulcer.
As the search for more efficacious and/or convenient treatment
modalities continues, it was an appropriate time to evaluate and
summarize the evidence on current treatment options.
O B J E C T I V E S
To summarize the evidence of drug treatments for treating Buruli
ulcer.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled clinical trials (RCTs) and prospective ob-
servational studies.
Types of participants
We included participants diagnosed as having Buruli ulcer due to
the presence of a suggestive lesion and any one of the following:
• a culture of M ulcerans from the lesion;
• a positive IS2404 dry-reagent-based PCR from a swab or
biopsy of the lesion;
• histopathological finding indicative of M ulcerans infection
(for example, necrotic granuloma, presence of AFB), irrespective
of age.
Types of interventions
We included studies that compared:
• antibiotic therapy to placebo or alternative therapy such as
surgery;
• different antibiotic regimens.
We also included prospective observational studies that evaluated
different antibiotic regimens with or without surgery.
Types of outcome measures
Primary outcomes
• Cure: healing of skin lesions without recurrence at 12
months or longer.
• Probable cure: healing of skin lesions with follow-up to 12
months.
• Possible cure: healing of skin lesions at follow-up.
Secondary outcomes
• Surgery.
• Healing time needed for wound closure.
• Reduction in ulcer size.
• Recurrence of skin lesion(s) after healing.
• Adverse effects.
• Paradoxical reactions.
Search methods for identification of studies
We attempted to identify all potential studies regardless of lan-
guage or publication status (published, unpublished, in press, and
in progress).
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Electronic searches
We searched the following databases using the search terms and
strategy described in Appendix 1: the Cochrane Infectious Dis-
eases Group Specialized Register; the Cochrane Central Register
of Controlled Trials ( CENTRAL), published in the Cochrane
Library ( Issue 11, 2017); MEDLINE ( PubMed; from 1966);
Embase ( Ovid; from 1947); and LILACS ( Latin American and
CaribbeanHealth Sciences Literature; BIREME) ( from1982). All
searches were conducted on 19 December 2017. We also searched
theUSNational Institutes ofHealthOngoingTrials Register Clin-
icalTrials.gov ( clinicaltrials.gov) and theWorld Health Organiza-
tion ( WHO) International Clinical Trials Registry Platform ( IC-
TRP) ( www.who.int/ictrp/search/en/) up to 19 December 2017
using “Buruli ulcer*” as a search term.
Searching other resources
We reviewed the reference lists of all included studies. We also
contacted leading researchers in this topic area to identify any
unpublished data.
Data collection and analysis
Selection of studies
Vittoria Lutje, the Cochrane Infectious Diseases Group (CIDG)
Information Specialist, searched the literature and retrieved studies
using the search strategy outlined inAppendix 1. In the initial stage
of selection, two review authors (Rie Roselyne Yotsu (RRY) and
Marty Richardson (MR)) independently screened the abstracts of
studies retrieved by the search to identify those that met the inclu-
sion criteria. We retrieved the full-text articles of published or un-
published potentially relevant study reports for further assessment.
Rie Roselyne Yotsu or Marty Richardson contacted the study au-
thors for further details regarding study methodology if eligibility
was unclear. A third review author (Norihisa Ishii (NI)) was con-
sulted when there was a difference of opinion between RRY and
MR. If there was still disagreement between the review authors,
we consulted one of the CIDG Co-ordinating Editors to reach a
consensus. We examined study reports to ensure that we included
multiple publications from the same study only once.
Data extraction and management
Two review authors (RRY and MR) extracted and summarized
data from the included studies on standardized data extraction
forms. Any differences of opinion were resolved through discus-
sion. If important data were missing from the included studies,
we contacted the study authors for further information.
We extracted the number of participants randomized and the num-
ber of participants followed up in each treatment arm, with a list
of each study’s inclusion and exclusion criteria, a description of
the intervention(s), and primary and secondary outcome mea-
sures. The data extraction form also included baseline character-
istics of participants in the control group such as age, sex, stage of
lesions, ulcer size,WHO category, diagnostic results, healing time,
side effects, outcome, post-treatment surgery, and recurrence. Rie
Roselyne Yotsu entered the data into Review Manager 5 (RevMan
2014).
For dichotomous outcomes, we extracted the number of partic-
ipants experiencing the event and the number of participants in
each treatment group. For continuous outcomes, we extracted
arithmetic means, standard deviations, and the numbers of par-
ticipants for each treatment group.
Assessment of risk of bias in included studies
All review authors (RRY, MR, and NI) independently assessed the
risk of bias for each included study. We assessed RCTs using the
Cochrane ‘Risk of bias’ assessment tool with seven domains of bias
including: random sequence generation, allocation concealment,
blinding of participants and personnel, blinding of outcome as-
sessment, incomplete outcome data, selective reporting, and other
potential sources of bias (Higgins 2011). We assessed prospective
observational studies in accordance with methods adopted from
‘A Cochrane Risk of Bias Assessment Tool: for Non-Randomized
Studies of Interventions’ (ACROBAT-NRSI) (Sterne 2014). We
assessed five domains of bias including: selection of participants
into the study, measurement of outcomes, incomplete outcome
data, selective reporting, and other potential sources of bias.
We assigned a judgement of either ‘high’, ‘low’, or ‘unclear’ risk of
bias for each component. We chose ‘unclear’ either when the avail-
able information was inadequate to judge or when it was neither
‘high’ nor ‘low’. Any discrepancies regarding ‘Risk of bias’ analysis
results were resolved through discussion. We consulted one of the
CIDG Co-ordinating Editors if necessary. We presented the find-
ings in a ‘Risk of bias’ table, and produced figures to summarize
the risk of bias across included studies. For domains that did not
pertain to the study design, we assigned ‘unclear risk of bias’ for
RCTs and ‘low risk of bias’ for prospective observational studies so
that all studies could be handled in a single ‘Risk of bias’ graph and
summary figure. We also labelled the study name and the domains
with the study design in order to enable differentiation between
the two study designs.
We further assessed the certainty of the evidence using theGRADE
approach for any RCTs for which we could apply this method
(Juni 2001). We used GRADEpro GDT software to construct a
‘Summary of findings’ table (GRADEpro GDT 2015).
Measures of treatment effect
For RCTs using dichotomous outcomes, we presented the effect of
treatment within studies as the risk ratio (RR) with corresponding
95% confidence interval (CI).
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Unit of analysis issues
Had we identified studies for inclusion that had multiple inter-
vention arms, we would have included data from these studies by
either combining treatment arms, or by splitting the control group
so that participants would only be included in the meta-analysis
once.
Dealing with missing data
In the case of missing data, we attempted to contact the study
authors to request the missing information. If the study authors
did not collect or assess the needed data as part of their study, or if
we received no response, we analysed the available data only using
a complete-case analysis.
Assessment of heterogeneity
Had we performed meta-analyses in this review, we would have
inspected forest plots visually to assess whether statistical hetero-
geneity was present.We would have deemedCIs that did not over-
lap as indicating statistical heterogeneity.
Assessment of reporting biases
We planned to assess reporting bias by using funnel plots, however
we did not create these as we did not perform any meta-analyses
in this review.
Data synthesis
We compared studies in terms of combination of antibiotics and
duration, whether adjunctive surgery was performed or not, and
lesion size/types in order to determine whether it was possible, and
appropriate, to perform meta-analyses. We consequently decided
that it was not possible to perform meta-analyses due to the small
number of studies with the same intervention, different inclu-
sion criteria (for example, some studies only included small lesions
while others included large lesions; some studies only included ul-
cerated lesions while others included non-ulcerated lesions), and
different follow-up/assessment time points. We presented the key
characteristics of included studies alongside outcome data in ta-
bles, and discussed the results of the included studies narratively.
We will refer to the methods described in the protocol should we
need to conduct analyses in future updates.
Subgroup analysis and investigation of heterogeneity
Had we detected substantial heterogeneity in meta-analyses, we
would have explored the possible causes of the heterogeneity
by performing subgroup analyses. Subgroups for investigation
included lesion sizes, clinical lesions (papule, nodule, plaque,
oedema, and ulcer), and surgical intervention.
Sensitivity analysis
We did not perform sensitivity analyses as we did not perform any
meta-analyses in this review.
R E S U L T S
Description of studies
Results of the search
We conducted literature searches up to 19 December 2017 and
identified 548 titles (Figure 1). While searching for additional
information on Arens 2015, we identified one study through its
conference proceeding (Beissner 2015), and one study through
ongoing trials (Barogui 2016). Two review authors (RRY andMR)
closely examined 75 full-text articles. We contacted the technical
team at the WHO for possible unpublished studies; there were
none other than those we identified. We identified two ongoing
trials on USNational Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (NCT01432925; NCT01659437).
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Figure 1. Study flow diagram.
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We identified six RCTs and 15 prospective observational studies
that met the inclusion criteria. Two review authors (RRY andMR)
independently extracted data for these studies.
Included studies
Study design
Six articles reported a total of five RCTs. The BURULICO study
was reported in two different articles with different outcomes (
Nienhuis 2010; Klis 2014; see BURULICO Study 2010).
A total of 15 articles reported prospective observational studies.
Five articles were from the same Australian group using the data of
Buruli ulcer patients from their registry that they had started col-
lecting in January 1998 (O’Brien 2007; O’Brien 2012; Friedman
2013; O’Brien 2013b; Friedman 2016), and evaluated a number
of different combinations of antibiotics. We identified two sets of
articles reporting data for the same groups of participants at dif-
ferent time points (Friedman 2013 and Friedman 2016; O’Brien
2007 andO’Brien 2012), thereforewe extracted data fromonly the
more recent papers (O’Brien 2012; Friedman 2016). Some partic-
ipants in O’Brien 2012, O’Brien 2013b, and Friedman 2016 may
be included in more than one study, as they were from the same
registry. Barogui 2016 combined participants of the BURULICO
Study 2010 and the ongoing NCT01432925 trial, therefore there
is overlap of participants. However, Barogui 2016 measured an
outcome (paradoxical reactions) that was not an outcome measure
of the original RCTs. We counted this study as an independent,
prospective observational study.
We henceforth describe results of the qualitative synthesis of five
RCTs and 13 prospective observational studies.
Interventions and comparisons
Randomized controlled trials
The included RCTs evaluated the following.
• Monotherapy in comparison to placebo, with surgery when
indicated: clofazimine in one trial (Revill 1973), and
sulfamethoxazole/trimethoprim in a second trial (Fehr 1994).
• Combination therapy:
◦ rifampicin + streptomycin before surgery with
different lengths of treatment (varying from two to 12 weeks), in
comparison to surgery alone (Etuaful 2005);
◦ rifampicin + streptomycin for four weeks followed by
rifampicin + clarithromycin for four weeks in comparison to
rifampicin + streptomycin for eight weeks, with surgery when
indicated (BURULICO Study 2010);
◦ rifampicin + dapsone for eight weeks in comparison to
no treatment, with no surgery in either arm (Espey 2002).
Prospective observational studies
Two studies evaluated different treatment regimens in multiple
treatment arms (O’Brien 2012; Friedman 2016). All of the other
prospective observational studies were single-arm studies. Prospec-
tive observational studies evaluated the following.
• Monotherapy with clofazimine for one to four weeks before
surgery (Lunn 1964).
• Combination therapy with rifampicin + streptomycin for:
◦ 12 weeks with surgery at week 4 (Kibadi 2010);
◦ eight weeks with surgery when indicated (Chauty
2007; Sarfo 2010; Adu 2013; Beissner 2015);
◦ eight weeks with surgery (Agbenorku 2011).
• Combination therapy with rifampicin + clarithromycin:
◦ rifampicin + clarithromycin for eight weeks, with
surgery when indicated (Chauty 2011);
◦ rifampicin + streptomycin for two weeks followed by
rifampicin + clarithromycin for six weeks, with surgery when
indicated (Phillips 2014a).
• Other combination therapy:
◦ rifampicin + either ciprofloxacin, clarithromycin, or
moxifloxacin, with no surgery or with limited debridement
(Friedman 2016);
◦ rifampicin + ciprofloxacin, rifampicin +
clarithromycin, rifampicin + clarithromycin + ethambutol,
ciprofloxacin + clarithromycin, rifampicin + moxifloxacin,
clarithromycin + ethambutol, rifampicin + ethambutol +
amikacin, or clarithromycin only, with surgery in all cases, in
comparison to surgery alone (O’Brien 2012);
◦ single or combination administration of rifampicin,
ciprofloxacin, clarithromycin, ethambutol, amikacin, and/or
moxifloxacin, with surgery when indicated (O’Brien 2013b);
◦ either rifampicin + streptomycin for eight weeks or
rifampicin + streptomycin for four weeks followed by rifampicin
+ clarithromycin for four weeks, with surgery when indicated
(Barogui 2016).
Location and participants
All studies were conducted in areas with high Buruli ulcer en-
demicity: of the RCTs, three were conducted in Ghana and one
in Côte d’Ivoire and in Uganda; of the prospective observational
studies, four were conducted in Ghana, three in Australia, two in
Benin, one in Uganda, one in Democratic Republic of Congo,
and one in Togo. Barogui 2016 was a joint study between Ghana
and Benin.
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Some studies set inclusion criteria for age and lesion type or size
given in diameter. Of the RCTs, the BURULICO Study 2010 re-
cruited participants over five years with lesion size less than 10 cm;
Etuaful 2005 recruited participants over 15 years with lesion size
less than 10 cm; and Espey 2002 recruited participants over four
years with ulcers. Of the prospective observational studies, Chauty
2011 recruited participants over five years with lesion size less than
10 cm; Phillips 2014a recruited participants over five years with
lesion size less than 15 cm; Kibadi 2010 recruited participants be-
tween three and 75 years with lesion size larger than 10 cm; and
the NCT01432925 trial (a part of Barogui 2016) recruited partic-
ipants over three years of age. All other included studies recruited
all age groups and lesion sizes.
Three RCTs, Fehr 1994; Etuaful 2005; BURULICO Study 2010,
and 10 prospective observational studies, Sarfo 2010; Agbenorku
2011; Chauty 2011; O’Brien 2012; Adu 2013; O’Brien 2013b;
Phillips 2014a; Beissner 2015; Barogui 2016; Friedman 2016, had
laboratory confirmation as part of their inclusion criteria. The
remaining included studies did not have laboratory confirmation
as an inclusion criterion.
Outcomes and length of follow-up
Outcomes in the RCTs varied. One trial measured “cure” (
BURULICO Study 2010), and one trial measured “possible cure”
(Revill 1973). Both trials also measured healing time (Revill 1973;
BURULICO Study 2010). Otherwise, change in ulcer size was
investigated in three trials (Fehr 1994; Espey 2002; Etuaful 2005),
recurrence in three trials (Revill 1973; Etuaful 2005; BURULICO
Study 2010), and adverse effects in three trials (Espey 2002;
Etuaful 2005; BURULICO Study 2010).
Of the prospective observational studies, seven studies measured
“cure” (Phillips 2004; Kibadi 2010; Sarfo 2010; Agbenorku 2011;
Chauty 2011; O’Brien 2012; Friedman 2016); one study mea-
sured “probable cure” (Chauty 2007); and three studies measured
“possible cure” (Lunn 1964; Adu 2013; Beissner 2015). Healing
time was investigated in five studies (Sarfo 2010; Chauty 2011;
Phillips 2014a; Beissner 2015; Friedman 2016), change in ulcer
size in one (Sarfo 2010), recurrence in eight (Chauty 2007; Kibadi
2010; Sarfo 2010; Agbenorku 2011; Chauty 2011; O’Brien 2012;
Phillips 2014a; Beissner 2015), adverse effects in eight (Lunn
1964; Chauty 2007; Sarfo 2010; Agbenorku 2011; Chauty 2011;
O’Brien 2012; Phillips 2014a; Friedman 2016), and paradoxi-
cal reactions in six studies (Sarfo 2010; O’Brien 2012; O’Brien
2013b; Phillips 2014a; Barogui 2016; Friedman 2016).
Follow-up period varied in the RCTs. Etuaful 2005 followed up
participants until one year after completion of treatment. In the
BURULICO Study 2010, Nienhuis and colleagues first followed
up participants until one year, and then Klis and colleagues re-
visited participants again during four to six years after treatment.
Two trials did not specify their follow-up time (Fehr 1994; Espey
2002). In the earlier study by Revill 1973, their follow-up pe-
riod ranged from 17 to 40 months, with a median of 32 months.
Follow-up in the prospective observational studies was one year
in six studies (Chauty 2007; Sarfo 2010; O’Brien 2012; O’Brien
2013b; Phillips 2014a; Friedman 2016). Otherwise, it was seven
months in Barogui 2016, 1.5 years in Chauty 2011, two years
in Agbenorku 2011 and Kibadi 2010, and not specified in Lunn
1964, Adu 2013, and Beissner 2015.
Excluded studies
We excluded 475 studies after title and abstract screening. We
assessed 75 full-text articles for eligibility, of which we excluded
37 on the basis of their study design (retrospective observational
studies, cross-sectional surveys, case series, or qualitative studies),
eight because they were either reviews or commentaries, five be-
cause they were conference proceedings, and four because they
were duplicates.
Risk of bias in included studies
We have summarized the risk of bias in included studies in Figure
2 and Figure 3.
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Figure 2. ‘Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ‘Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Randomized controlled trials
Of the five included RCTs, only BURULICO Study 2010 used
adequate methods. Otherwise, either methods were either inade-
quate or details were poorly reported in the remaining studies.
Prospective observational studies
Of the 13 prospective observational studies, we rated seven recent
studies as at low risk of bias (Sarfo 2010; Agbenorku 2011; Adu
2013; O’Brien 2013b; Phillips 2014a; Barogui 2016; Friedman
2016). The older studies were associated with a higher risk of bias
(Lunn 1964; Chauty 2007).
Allocation
Of the five RCTs, two were blinded and were rated as at low risk
of bias (Revill 1973; BURULICO Study 2010). Otherwise, no
information, Espey 2002; Etuaful 2005, or no clear statement,
Fehr 1994, was provided, and these studies were rated as at unclear
risk of bias.
Blinding
Of the five RCTs, two were blinded and were rated as at low
risk of bias (Revill 1973; Fehr 1994). Otherwise, the RCTs were
open-label, BURULICO Study 2010, or no clear statement was
provided, Espey 2002; Etuaful 2005, but were rated as at low risk
of bias as the outcome was unlikely to be influenced by lack of
blinding.
Incomplete outcome data
Of the five RCTs, we rated one as at high risk of bias, as 10 out of
30 participants (33%) were lost to follow-up (Espey 2002). The
proportion of missing data was relatively large in one RCT (6/18
participants, 33%) (Fehr 1994), however reasons for exclusions/
missing data were relatively well balanced or unlikely to be related
to true outcome, and the RCT was rated as at low risk of bias.
Otherwise, no participants, Etuaful 2005, or a minimal number
of participants, Revill 1973; BURULICO Study 2010, were lost
to follow-up, and we judged these RCTs as at low risk of bias.
Of the 13 prospective observational studies, we rated two studies as
at high risk of bias: the assessment time point was unclear in Lunn
1964, and 17 participants were lost to follow-up during the study
period but were included in the final analysis in Chauty 2007.
Otherwise, either no participants, Kibadi 2010; Agbenorku 2011;
Chauty 2011; O’Brien 2012; Adu 2013; O’Brien 2013b; Beissner
2015; Barogui 2016; Friedman 2016, or a minimal number of
participants, Sarfo 2010; Phillips 2014a, were lost to follow-up,
and we considered these studies as at low risk of bias.
Selective reporting
Of the five included RCTs, we rated one as at unclear risk of bias as
there were no predefined outcomes (Lunn 1964). All of the other
RCTs reported all expected outcomes, and we rated these as at low
risk of bias.
All 13 prospective observational studies reported all expected out-
comes and were rated as at low risk of bias.
Other potential sources of bias
Five studies either did not have laboratory confirmation as their
inclusion criteria or only performed laboratory exams in a por-
tion of their participants, therefore non-Buruli ulcer cases may be
included in their study results (Lunn 1964; Revill 1973; Espey
2002; Chauty 2007; Kibadi 2010). The standard treatment for
Buruli ulcer has transitioned from surgery to drugs plus surgery as
adjunctive treatment after the recommendation of drug treatment
by the WHO in 2004 (WHO 2014), and this may have created
some bias.
Potential comorbidities such as osteomyelitis, HIV/AIDS, dia-
betes mellitus, cancer, and use of immunosuppressant drugs may
have affected some results, especially on severity and healing rate
and time. Two studies reported on comorbidities of their study
participants: 9.5% in Friedman 2016 and 16.3% inO’Brien 2012;
there may be an overlap of participants in these two studies.
Effects of interventions
See: Summary of findings for the main comparison Rifampicin
combined with streptomycin compared with surgery alone
for Buruli ulcer; Summary of findings 2 Rifampicin with
clarithromycin compared with rifampicin with streptomycin in
the consolidation phase for Buruli ulcer
We first assess the effects of a variety of treatments on healing and
recurrence, stratified by monotherapy and combination therapy.
We then summarise adverse effects andparadoxical reactions across
all comparisons.
Healing and recurrence
Monotherapy
See Table 1.
One RCT and one prospective observational study evaluated the
efficacy of clofazimine, and one RCT evaluated the efficacy of sul-
famethoxazole/trimethoprim. All three studies had small sample
sizes, and no treatment effects were demonstrated.
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Clofazimine
Revill 1973 compared clofazimine to placebo, with similar recur-
rence in the two arms (clofazimine 8/51 (15.7%); placebo 10/
54 (18.5%); difference 2.8%, 95% confidence interval (CI) not
given). The authors examined a subgroup of participants with
non-ulcerated lesions whowere withheld from immediate surgery:
the number that healed was slightly higher with clofazimine, but
the difference was small, and this was a post hoc subgroup analy-
sis (clofazimine, 5/13 (38%); placebo, 6/21 (29%)). The median
healing time was measured in this same subgroup also those with
a lesion less than 5 cm in diameter (clofazimine, 8 participants;
placebo, 17 participants) and was 21 weeks and 14 weeks, respec-
tively.
One prospective observational study, Lunn 1964, examined the
effects of clofazimine with surgery in 10 participants with ulcers.
Six participants (60%) achieved complete healing in 3 to 12weeks.
The remaining four participants were still under treatment for
their ulcers at the time of reporting.
Sulfamethoxazole/trimethoprim
Fehr 1994 compared sulfamethoxazole/trimethoprim to placebo
in 12 participants with ulcers. The mean ulcer size in the sul-
famethoxazole/trimethoprim group at baseline was 73.8 cm2 (9 to
247) and in the placebo group was 38.7 cm2 (15 to 80). The au-
thors reported that sulfamethoxazole/trimethoprim reduced ulcer
size by an average of 10.9%, while an average increase of 24.5%
was observed in the placebo group (P = 0.15). The percentage
ulcer area covered by granulation tissue at study end was 92% in
the sulfamethoxazole/trimethoprim group and 57% in the placebo
group (P = 0.17).
Combination therapy
Rifampicin combined with streptomycin
See Table 2.
One RCT and six prospective observational studies investigated
the efficacy of rifampicin and streptomycin. Five prospective ob-
servational studies evaluated this regimen administered for 8weeks
(828 participants) with surgery given to either all participants or a
select group. Four studies reported healing rates for all participants,
regardless of whether they had received surgery or not (84.5% to
100%, assessed at various time points). Four studies reported heal-
ing rates for participants who received combination therapy alone
(48% to 95%, assessed at various time points).
One RCT, Etuaful 2005, examined 21 participants with non-ul-
cerative lesions to test the efficacy of rifampicin and streptomycin.
They divided the participants into 5 groups: 4 groupswere given ri-
fampicin and streptomycin for 2, 4, 8, and 12 weeks before surgery
respectively, and one group received only surgery. No recurrence
was observed in participants in any group receiving combination
therapy at 12 months, compared with one case of recurrence in a
participant who received only surgery. No difference in recurrence
was observed between these two groups (risk ratio (RR) 0.12, 95%
CI 0.01 to 2.51; Figure 4; Analysis 1.1). Reduction in lesion sur-
face area in participants who received rifampicin and streptomycin
was the highest (52%) in the group that underwent four weeks of
the regimen before surgery.
Figure 4. Forest plot of comparison: 1 Rifampicin plus streptomycin (experimental) versus surgery alone
(control), outcome: 1.1 Recurrence.
One prospective observational study, Kibadi 2010, examined ri-
fampicin and streptomycin given for 12 weeks with surgery per-
formed at week 4, in 92 participants with ulcerative lesions mea-
suring more than 10 cm in diameter. The study showed a high
healing rate at week 12 (85/92, 92.4%) and low recurrence rate at
2 years (2/92, 2.2%).
Five prospective observational studies examined treatment with
rifampicin and streptomycin for eight weeks (Chauty 2007; Sarfo
2010; Agbenorku 2011; Adu 2013; Beissner 2015). In one study
all participants received surgery either during or after treatment
(in this study surgery included debridement and skin grafting,
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not just excision) (Agbenorku 2011); in one study a select group
received surgery after assessment at week 4 and week 8 (Chauty
2007); and in three studies a select group of participants received
after eight weeks of treatment (Sarfo 2010; Adu 2013; Beissner
2015).
• Where surgery was given to a select group participants,
surgery rate differed among studies: 5% in Sarfo 2010, 27% in
Beissner 2015, 52% in Chauty 2007, and 52% in Adu 2013.
• Four studies reported healing rates for all participants,
regardless of whether they received surgery or not: 84.5% in
Beissner 2015, 96.3% in Agbenorku 2011, 99.3% in Sarfo 2010
and 100% in Chauty 2007.
• Four studies reported healing rates for participants who
received combination therapy alone: 48% at week 8 in Adu
2013, 48% after week 8 in Chauty 2007, 69.8% after minimum
of 6 months follow-up in Beissner 2015, and 95% at 12 months
in Sarfo 2010.
• Follow-up showed recurrence was unusual: 0% in Sarfo
2010 and Beissner 2015, 0.5% in Agbenorku 2011, and 1.4% in
Chauty 2007.
Rifampicin combined with clarithromycin
See Table 3.
Two prospective observational studies (51 participants) evaluated
the use of rifampicin and clarithromycin. Both studies included
surgery, either to all participants or a select group. All participants
were healed at 12 months.
Chauty 2011 evaluated rifampicin and clarithromycin for eight
weeks in 30 participants with lesions measuring less than 10 cm in
diameter. They reported a high healing rate at 12 months with no
recurrence at 18 months (30/30, 100%). Half of the participants
(50%) healed without any form of surgery; 11 participants (37%)
healed with limited surgery including curettage of the lesion or a
minor excision; and 4 participants (13%) healed with extensive
surgery including major excision followed by skin grafting.
O’Brien 2012 evaluated rifampicin and clarithromycin with
surgery in 21 participants and reported a high healing rate (100%)
and no recurrence at one year. Duration of the regimen was de-
termined by the attending physician.
Rifampicin with streptomycin initially, changing to
rifampicin with clarithromycin in consolidation phase
See Table 3.
OneRCT and one prospective observational study examined heal-
ing rates starting with rifampicin and streptomycin, and then
swapping to rifampicin and clarithromycin, with surgery as indi-
cated. Both studies only included participants with small lesions,
and more than 90% of participants healed without surgery.
One RCT, BURULICO Study 2010, evaluated a regimen of ri-
fampicin plus streptomycin for 4 weeks followed by rifampicin
plus clarithromycin for 4 weeks in 151 participants with lesions
measuring less than 10 cm in diameter. They compared this to
the standard treatment at the time of eight weeks of rifampicin
and streptomycin. Both groups achieved high healing rates at 12
months without surgery (a small number in each group had skin
grafting): new regimen 68/75 (91%), standard regimen 73/76
(96%). There was no significant difference in healing rate or re-
currence between the two groups (RR 0.94, 95% CI 0.87 to 1.03;
not estimable due to 0 cases in both groups; Figure 5, Analysis
2.1; Figure 6; Analysis 2.2) or in healing time.
Figure 5. Forest plot of comparison: 2 Rifampicin combined with clarithromycin versus rifampicin
combined with streptomycin in the consolidation phase, outcome: 2.1 Cure.
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Figure 6. Forest plot of comparison: 2 Rifampicin plus clarithromycin (experimental) versus rifampicin plus
streptomycin in the consolidation phase (control), outcome: 2.2 Recurrence at 12 months.
One prospective observational study, Phillips 2014a, evaluated a
regimen of rifampicin plus streptomycin for 2 weeks followed by
rifampicin plus clarithromycin for 6 weeks in 43 participants with
lesions measuring less than 15 cm in diameter. Forty of 41 (98%)
participants achieved healing by 52 weeks without surgery.
Novel combination therapy
See Table 4.
One RCT and two prospective observational studies investigated
the efficacy of combinations of one to three drugs from the fol-
lowing: rifampicin, dapsone, ciprofloxacin, clarithromycin, mox-
ifloxacin, ethambutol, amikacin, and azithromycin. High healing
rates and low recurrence were achieved in the two prospective ob-
servational studies.
One RCT, Espey 2002, examined the efficacy of rifampicin and
dapsone for 8 weeks against placebo in 30 participants with ul-
cerative lesions. No significant differences were observed for clin-
ical improvement as judged by Buruli ulcer specialists using pho-
tographs (P = 0.51). A significant change in ulcer size after two
months was observed (P = 0.02), however there was a significant
difference in the initial ulcer size between the two groups.
Two prospective observational studies from the Australian group
tested combinations of one to three oral antibiotics including ri-
fampicin, ciprofloxacin, clarithromycin, moxifloxacin, ethambu-
tol, amikacin, and azithromycin. Friedman 2016 evaluated partic-
ipants who received the regimen with no surgery or with limited
surgical debridement. Among the 160 participants in their reg-
istry, 28 participants (17.5%) who received extensive surgery were
excluded, leaving 132 participants for their analysis. They reported
that 131/132 (99%) participants healed at one year, among whom
101 (76.5%) participants healed with antibiotics alone. Median
duration of antibiotic treatment was 56 days (interquartile range
24 to 96 days), and 22 participants (16.7%) needed fewer than 56
days to reach healing. O’Brien 2012 compared participants who
were treated with antibiotics plus surgery to surgery alone. All 90/
90 participants (100%) who underwent combined treatment with
antibiotics plus surgery healed. Fourteen (30%) participants who
received only surgery had recurrence. As the participants were re-
trieved from the same registry in these two studies, some partici-
pants may contribute data to more than one of the studies.
Adverse effects
Three RCTs evaluated adverse effects, of which two reported none
(Espey 2002; Etuaful 2005). One RCT evaluated long-term ad-
verse effects of streptomycin three to six years after treatment
(BURULICO Study 2010). Among those that could be retrieved
from the past BURULICO study (n = 127), ototoxicity was ob-
served in 23% of adults in the 4-week streptomycin group and
40% of adults in the 8-week streptomycin group (total n = 41),
and in 28% of children in the 4-week streptomycin group and
26% of children in the 8-week streptomycin group (total n = 86).
Nephrotoxicity during treatment was observed in 9% of adults in
the 4-week streptomycin group and 20% of adults in the 8-week
streptomycin group, and in 5% of children in the 4-week strep-
tomycin group and 20% of children in the 8-week streptomycin
group. At long-term follow-up, one adult (2.4%) and two chil-
dren (2.4%) were classified as having long-term nephrotoxicity, all
from the 8-week streptomycin group.
Eight prospective observational studies evaluated adverse effects,
of which two reported none (Chauty 2007 (rifampicin, strepto-
mycin) and Agbenorku 2011 (rifampicin, streptomycin)). One
study reported no discontinuation of antibiotics (rifampicin, clar-
ithromycin) due to adverse effects (Chauty 2011). Lunn 1964
reported one participant with gastrointestinal intolerance from
clofazimine. Sarfo 2010 reported one participant with dizziness
and one with vomiting and dizziness from streptomycin, and one
participant with rash probably from rifampicin. Phillips 2014a
reported one participant with ototoxicity from streptomycin.
O’Brien 2012 reported that of 90 participants who received an-
tibiotic treatment, 28 (31%) developed adverse effects including
gastrointestinal intolerance, hepatitis, rash, hypoglycaemia, joint
or tendon effects, palpitations, and hallucinations. Friedman 2016
reported that 21 of the 132 participants (16%) developed adverse
effects (unspecified) that required cessation of one or more antibi-
otics during treatment.
Paradoxical reactions
See Table 5.
Six prospective observational studies evaluated paradoxical reac-
tions (Sarfo 2010; O’Brien 2012; O’Brien 2013b; Phillips 2014a;
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Barogui 2016; Friedman 2016), of which two studies evaluated
solely this outcome (O’Brien 2013b; Barogui 2016).
The incidence of paradoxical reactions ranged from 1.9% in Sarfo
2010 to 26% in Friedman 2016.Median onset time of paradoxical
reactions ranged from 5.6 weeks (39 days) in O’Brien 2013b to 12
weeks in Phillips 2014a. As the participants were retrieved from
the same registry in three studies (O’Brien 2012; O’Brien 2013b;
Friedman 2016), some participants may contribute data to more
than one of the studies.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Rifampicin with clarithromycin compared with rifampicin with streptomycin in the consolidation phase for Buruli ulcer
Patient or population: people with Buruli ulcer, early lesions measuring less than 10 cm in diameter, aged 5 years or older
Settings: Ghana
Intervention: rif ampicin with streptomycin, followed by rifampicin with clarithromycin af ter 4 weeks
Comparison: rif ampicin with streptomycin cont inued
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Streptomycin contin-
ued
Clarithromycin substi-
tute
Curea 96 per 100 90 per 100
(84 to 99)
RR 0.94
(0.87 to 1.03)
151
(1 trial)
⊕⊕©©
LOWb
due to imprecision
We do not know if the
treatment is superior to
the control.
* The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95%CI) is based on the
assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
Abbreviations: CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.
aCure is def ined as ‘‘healing of skin lesions without recurrence at 12 months or longer.’’ There were no recurrences in this
study.
bDowngraded by 2 for imprecision: very few events and wide CIs.
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D I S C U S S I O N
Summary of main results
See Summary of findings for the main comparison and Summary
of findings 2.
We included 18 studies, of which five were RCTs, in this review.
Earlier studies conducted before 2000 that assessed monother-
apy (clofazimine, sulfamethoxazole/trimethoprim) demonstrated
no treatment effect. The remaining studies assessed combination
therapy with or without surgery. The main regimens included ri-
fampicin plus streptomycin, rifampicin plus clarithromycin, and
rifampicin plus streptomycin switching to rifampicin plus clar-
ithromycin during the consolidation phase.
It is evident that antimicrobials are important in treating Buruli ul-
cers; this was an already established fact, but also learned from this
review. Different combinations of antibiotics are given for eight
weeks to treat Buruli ulcer, irrespective of the stage.However, there
were insufficient studies and data to be able to determine which
regimen is the most effective. In 2004, the WHO first recom-
mended a combination of rifampicin and streptomycin for eight
weeks (WHO 2014). However, there is no evidence from RCTs
to support this treatment. Five prospective observational studies
tested this regimen, which reported healing rates from 84.5% to
100% with or without surgery. Four studies reported healing rates
for participants who received combination therapy alone to be
from 48% to 95%. The time points assessed in the studies varied,
and therefore a comparison or calculation of a combined healing
rate was not possible.
There has recently been movement from the current regimen,
which requires injection, to an all-oral treatment, with the goal
of reducing the burden of treatment for patients. Of the stud-
ies included in this review, BURULICO Study 2010 was the
only RCT with adequate methods. This study tested rifampicin
plus streptomycin for four weeks followed by rifampicin and clar-
ithromycin for four weeks against rifampicin plus streptomycin
for eight weeks, so that the patients will receive fewer injections of
streptomycin. The study showed that there was no significant dif-
ference in healing rate and time between the two regimens. Other
studies have investigated different combinations of oral drugs, with
most regimens yielding high healing rates (Chauty 2011; O’Brien
2012; Friedman 2016). The study sample sizes were small, and
their study design was weak to examine the effects of these regi-
mens, however these studies show the potential of all-oral treat-
ments. The WHO currently lists use of rifampicin (10 mg/kg
once daily) with either streptomycin (15mg/kg once daily) or clar-
ithromycin (7.5 mg/kg twice daily) for eight weeks as the treat-
ment choices for Buruli ulcer, depending on the patient (WHO
2012; WHO 2017).
When assessing the efficacy of treatments for Buruli ulcers, le-
sion size, lesion type, and whether surgery was applied or not are
important factors to be considered. We attempted to perform a
subanalysis, but this was not possible due to the heterogeneity of
studies. It may also be important to consider the impact of the
severity of lesions (WHO category) on treatment efficacy, how-
ever not all studies reported these data. It is important to note that
some studies that reported high healing rates recruited only par-
ticipants with small lesions, which may be important to consider
when interpreting the results from these studies (Etuaful 2005;
BURULICO Study 2010; Chauty 2011; Phillips 2014a).
Six prospective observational studies measured incidence of para-
doxical reactions, which ranged from 1.9% to 26%. The patho-
genesis of paradoxical reactions remains unclear, but recent studies
report a possible association with antibiotic treatment and types of
antibiotics used (O’Brien 2009; Nienhuis 2012; O’Brien 2013b).
Overall completeness and applicability of
evidence
All studies included both males and females. With regards to age,
participants from African countries were younger compared to
those fromAustralia, which could have influenced the results. This
is reflected by the different age distributions of the affected pop-
ulation between the two areas (Asiedu 1998; Wansbrough-Jones
2006; Boyd 2012). Comorbidities (includingHIV) in participants
were uncommon, or those with comorbidities were excluded from
the study, with the exception of the Australia group studies. Rates
of comorbidities in the two Australian studies (9.5% and 16.3%)
could have affected their study results.
Five studies (26%) diagnosed Buruli ulcer based only on clinical
presentation, otherwise all studies had laboratory confirmation
of Buruli ulcer either by Ziehl-Neelsen test for AFB, polymerase
chain reaction (PCR), or histopathology. All recent studies (after
2007) had laboratory confirmation of Buruli ulcer as part of their
inclusion criteria.
Treatment was often given for eight weeks, which has been the
WHO recommendation since 2004, and different durations were
not tested. Dosages of the drugs were the same between studies:
10 mg/kg/day for rifampicin, 15 mg/kg/day for streptomycin, and
7.5mg/kg/day for clarithromycin. Interventionwith surgerymade
it a challenge to compare the outcomes between studies. However,
it is an important adjunctive intervention to drugs for treating
Buruli ulcer, and participants who received surgery were included
in the study results. The extent/definition of surgical intervention
differed between studies: for example, skin grafting was not con-
sidered to be surgery in BURULICO Study 2010 and Friedman
2016. Furthermore, the decision of when to intervene with surgery
differs among surgeons/clinicians, and this may have affected the
results. It is also important to note that earlier studies tended to
perform surgery more often than current studies, as it used to be
the standard treatment.
Healing as defined by complete epithelialization was the primary
outcome in most studies, but not in the earlier studies, where it
was change in ulcer size (Fehr 1994; Espey 2002; Etuaful 2005).
The only other outcome that was comparable between studies
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was recurrence. Assessment time points differed between studies,
whichmade it impossible to compare or synthesize the results from
different studies.
Certainty of the evidence
The certainty of the evidence was very low.
Potential biases in the review process
We attempted to limit bias in the review process. Vittoria Lutje, the
Cochrane Infectious Diseases Group Information Specialist, con-
ducted the literature searches, and it is unlikely that these searches
missed any major studies; however, we cannot rule out the possi-
bility that we missed some small unpublished studies.
We included prospective observational studies in this review as
there was a very limited number of RCTs investigating this topic.
This decision was made after a number of discussions between
the authors, the Cochrane Infectious Diseases Group, and their
reviewers. While this may have created some bias in this review, we
have tried to minimize bias by reporting the results of prospective
observational studies separately from RCTs.
To limit bias in the study selection process and data extraction, we
independently examined the search results, selected studies, and
extracted data.
Agreements and disagreements with other
studies or reviews
There were no other studies or reviews with which to compare this
review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
People with Buruli ulcers should receive drug therapy. This is
obvious and not the subject of this Cochrane Review.
Regarding choice of drug and duration of treatment, the studies
included in this review did not provide substantive evidence to
guide recommendations. The differences in efficacy between drugs
is still uncertain, although the included studies at low risk of bias
did demonstrate a high healing rate of Buruli ulcer lesion(s) with
the use of combined drug therapy, with or without surgery. How
different sizes/lesions/stages of the disease may contribute to heal-
ing and which kind of lesions are in need of surgery were unclear
from the included studies. These factors need to be considered, as
does the practicality of the treatment in resource-limited settings
where most people with Buruli ulcer reside, when guiding recom-
mendations for the treatment of Buruli ulcer.
The current available evidence does not support the use of ri-
fampicin and streptomycin for an eight-week duration, which has
been the standard regimen used in endemic African countries.
Implications for research
There were two ongoing trials at the time of publication of
this Cochrane Review. One trial is a multicentre study between
Ghana and Benin testing rifampicin and clarithromycin for eight
weeks (NCT01659437). The other trial is testing the timing
of surgery with rifampicin and streptomycin for eight weeks
(NCT01432925). The preliminary results of these studies were
reported at the World Health Organization Buruli Ulcer Meeting
in March 2017 and will be included in our updated review.
Conducting field trials to test treatment effect of Buruli ulcer is
complex and challenging, as:
• there are a limited number of patients (2000 to 5000
annual cases globally); and
• there are multiple treatments that contribute to healing
including surgery and wound care and not just drugs.
Although we assessed the certainty of the evidence of the studies
included in this review as low, researchers have worked hard to
generate this body of evidence under these circumstances.
Further researchwill be useful testing different regimens, including
the possibility of new drugs/combinations; different durations of
treatment depending on the lesion stage; and timing of surgical
interventions. Antituberculosis drugs that arrived recently on the
market could also be useful in the treatment of Buruli ulcer and
need to be tested, yet the high cost of these drugs is a concern for
use in resource-limited settings, where most patients reside. Cost
analysis of treatment - which is often neglected and needs more
attention - is therefore also an important area for investigation. As
Buruli ulcer is a toxic disease while it is an infection, antitoxins
or other systemic drugs may bring about a breakthrough in the
treatment of the disease and are interesting areas for exploration.
The development of reliable and low-cost point-of-care diagnostic
tools are needed to promote a better body of evidence for Buruli
ulcer treatment. The primary diagnostics to confirm the disease is
currently polymerase chain reaction (PCR), which is not readily
available inmany endemic areas. Assessment time points of healing
and recurrence should be made uniform so as to allow comparison
between studies, and such action should be initiated. This can be
facilitated by the development of tools to quantify healing. For
example, level of mycolactone in lesions, blood, or urine could be
a candidate for this purpose in the future when quantitative test
of mycolactone will be made easier to use. Wound care is another
essential focus for research in Buruli ulcer, which may also benefit
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other diseases with ulcers. Operational research in order to detect,
diagnose, and treat patients early also needs to be promoted.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Adu 2013
Methods Prospective observational study
Participants Inclusion criteria: clinically + laboratory-confirmed BU (exclusion: none stated)
Laboratory confirmation: either by ZN test for acid-fast bacilli (AFB), PCR, or
histopathology
Enrolled: 126 participants
Participant characteristics: 64 males, 50.8%; mean age 29.8 (range, 1 year 3 months to
98 years)
Lesion types: ulcer 116 (92%), papule 1 (0.5%), nodule 2 (1.5%), oedema 4 (3%),
chronic osteomyelitis 2 (1.5%), contractures 2 (1.5%) (1 participant with both ulcer
and contracture)
WHO category I: 12 (10%), category II: 43 (34%), category III: 71 (56%)
Interventions Rifampicin (10 mg/kg/day) + streptomycin (15 mg/kg/day), 8 weeks, with surgery
Surgery: when indicated after antibiotic treatment
Follow-up: N/A
Outcomes “Healed without surgery”, assessed at 8 weeks
Standardized outcome: possible cure
Notes Trial location: Ghana
Enrolment dates: January 2010 to December 2012
The primary objective of the study was to document the complications of BU and the
reconstructive surgery performed in patients whose lesions were not completely healed
after 8 weeks of antibiotic treatment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (Trials) High risk -
Allocation concealment (Trials) High risk -
Blinding of participants and personnel
(Trials)
High risk -
Blinding of outcome assessment (Trials) High risk -
Selection of participants into the study
(Prospective observational studies)
Low risk Selection not related to intervention or outcome.
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Adu 2013 (Continued)
Measurement of outcomes (Prospective ob-
servational studies)
Low risk Objective outcome measure (healing)
Incomplete outcome data / missing data
(All studies)
Low risk No missing data
Selective reporting (All studies) Low risk Reported all expected outcomes
Other bias Low risk No other bias identified.
Agbenorku 2011
Methods Prospective observational study
Participants Inclusion criteria: clinically + laboratory-confirmed BU (exclusion: none stated)
Laboratory confirmation: any 2 positives of ZN test for AFB, PCR, and histopathology
Enrolled: 189 participants
Participant characteristics: 113 males, 60%; age N/A
Lesion types: ulcer 145 (76.7%), nodule 38 (20.1%), plaque 6 (3.2%)
WHO category I: 44 (22.3%), categories II + III: 145 (76.7%)
Interventions Rifampicin (10 mg/kg/d) + streptomycin (15 mg/kg/d), 8 weeks, with surgery
Surgery: all cases
Follow-up: 2 years after discharge from hospital
Outcomes 1. Healing rate
2. Recurrence
3. Adverse effects
4. Mean hospital stay days
5. Number of new BU cases and their disease stage at the study site after counselling
and health education activities
Standardized outcome: cure
Notes Trial location: Ghana
Enrolment dates: January 2005 to December 2005
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (Trials) High risk -
Allocation concealment (Trials) High risk -
Blinding of participants and personnel
(Trials)
High risk -
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Agbenorku 2011 (Continued)
Blinding of outcome assessment (Trials) High risk -
Selection of participants into the study
(Prospective observational studies)
Low risk Selection not related to intervention or outcome.
Measurement of outcomes (Prospective ob-
servational studies)
Low risk Objective outcome measure (healing)
Incomplete outcome data / missing data
(All studies)
Low risk 3 participants (3.2%) were lost to follow-up but for
different outcomes
Selective reporting (All studies) Low risk Reported all expected outcomes
Other bias Low risk No other bias identified.
Barogui 2016
Methods Prospective observational study
Participants Inclusion and exclusion criteria: refer to BURULICO Study 2010 and NCT01432925
Enrolled: 241 participants; 150 from BURULICO Study 2010 and 91 from
NCT01432925
Participant characteristics: 88 (37%) males, mean (SD) 16.2 (13.2) years
Lesion types: ulcer 108 (45%), nodule 32 (13%), plaque 56 (23%), oedema 11 (5%),
mixed 34 (14%)
WHO category I: 69 (29%), category II: 133 (55%), category III: 39 (16%)
Interventions Refer to BURULICO Study 2010 and NCT01432925
Outcomes Paradoxical reaction defined by an initial decrease of the lesion size followed by 2 con-
secutive increases
Notes Trial location: Ghana and Benin
Enrolment dates: BURULICO Study 2010, 2006 to 2008; NCT01432925, 2011 to
2015
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (Trials) High risk -
Allocation concealment (Trials) High risk -
Blinding of participants and personnel
(Trials)
High risk -
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Barogui 2016 (Continued)
Blinding of outcome assessment (Trials) High risk -
Selection of participants into the study
(Prospective observational studies)
Low risk Selection not related to intervention or outcome.
Measurement of outcomes (Prospective ob-
servational studies)
Low risk Objective outcomes clearly defined.
Incomplete outcome data / missing data
(All studies)
Low risk No loss to follow-up
Selective reporting (All studies) Low risk Reported all expected outcomes
Other bias High risk Paradoxical reaction was only defined clinically by le-
sion size; no exams to support diagnosis
Beissner 2015
Methods Prospective observational study
Participants Inclusion criteria: clinically + laboratory-confirmed BU; any age (exclusion: laboratory-
unconfirmed cases)
Laboratory confirmation: IS2404 dry-reagent-based PCR
Enrolled: 199 eligible participants; 70 dropouts (35.2%); 129 participants analysed
Participant characteristics: 60 males, 46.5%; median 10 years, range 2 to 68 years
Lesion types: ulcer 73 (76.7%), nodule 19 (14.7%), plaque 26 (20.2%), oedema 11 (8.
5%)
WHO category I: 59 (45.7%), category II: 44 (34.1%), category III: 26 (20.2%)
Interventions Rifampicin (10 mg/kg/d) + streptomycin (15 mg/kg/d), 8 weeks
Surgery: when indicated
Follow-up: follow-up visits were conducted January to April 2013 (110 participants) and
May to June 2014 (19 participants) (> 6 months elapsed since the end of antimicrobial
treatment)
Outcomes 1. Healed with or without surgery
2. Healing time
3. Secondary lesions
4. Functional limitations
5. Recurrence until the follow-up visit
Standardized outcome: possible cure
Notes Trial location: Togo
Enrolment dates: September 2007 to November 2013
Risk of bias
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Beissner 2015 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (Trials) High risk -
Allocation concealment (Trials) High risk -
Blinding of participants and personnel
(Trials)
High risk -
Blinding of outcome assessment (Trials) High risk -
Selection of participants into the study
(Prospective observational studies)
High risk Only 129 out of 199 eligible patients could be re-
trieved and enrolled
Measurement of outcomes (Prospective ob-
servational studies)
Low risk Objective outcome measure (healing)
Incomplete outcome data / missing data
(All studies)
Low risk No missing data
Selective reporting (All studies) Low risk Reported all expected outcomes
Other bias Low risk No other bias identified.
BURULICO Study 2010
Methods Randomized controlled trial
Participants Inclusion criteria: clinically + laboratory-confirmed BU; aged 5 years or older, had a
reported disease duration of less than 6 months, and had lesions with a cross-sectional
diameter (indurated area) of 10 cm or less (exclusions: pregnancy, drug intolerance, and
renal, hepatic, and acoustic impairment)
Laboratory confirmation: IS2404 dry-reagent-based PCR
Enrolled: 151 participants; 143 with infection confirmed by PCR, 5 with infection
confirmed by other methods, 3 cases were clinical diagnosis
Participant characteristics: intervention group 19 (25%) males, median 12 years (IQR
9 to 22); control group 27 (36%) males, median 12 years (IQR 8 to 18)
Lesion types: ulcer 59 (39.1%), non-ulcer 92 (60.9%)
WHO category I: 58 (38.4%), category II + III: 93 (61.16%)
Interventions 1. Rifampicin (10 mg/kg/day) + streptomycin (15 mg/kg/day), 4 weeks followed by
rifampicin (10 mg/kg/day) + clarithromycin (7.5 mg/kg/day), 4 weeks
2. Rifampicin (10 mg/kg/day) + streptomycin (15 mg/kg/day), 8 weeks
Surgery: when indicated
Follow-up: once a week participants were given study drugs to take to the nearest health
facility to receive directly observed treatment for the subsequent days, with daily wound
care. Participants with complicated lesions were hospitalized
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BURULICO Study 2010 (Continued)
Participants were followed up at weekly intervals during the first 8 weeks; at week 10,
week 12, and then monthly to week 36, and bimonthly to week 52. Study visits included
clinical assessment with reporting of adverse effects, measurement of lesion size (if not
healed) by tracing onto an acetate sheet, and photography of the lesion
Outcomes 1. Healed without surgery or recurrence (cure)
2. Cumulative proportion of healing
3. Difference in healing time between the 2 groups
4. Skin grafts
5. Recurrence
6. Functional impairment
7. Adverse effects (ototoxicity, nephrotoxicity, abdominal discomfort) during
treatment
8. Long-term adverse effects (ototoxicity, nephrotoxicity) (Klis 2014)
Notes Trial location: Ghana
Enrolment dates: April 2006 to January 2008
HIV antibody testing was done with cold-stored sera after completion of the study, in
which 3 (2%) participants were found positive
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (Trials) Low risk Computer-generated minimization
Allocation concealment (Trials) Low risk Assigned allocation was sent from a central site by text
message to study co-ordinator
Blinding of participants and personnel
(Trials)
Low risk Open-label, but outcome unlikely to be affected by par-
ticipant knowledge of treatment group
Blinding of outcome assessment (Trials) Low risk Open-label, but primary endpoint also assessed by
blinded wound experts, and the results concurred with
those from the primary analysis
Selection of participants into the study
(Prospective observational studies)
Unclear risk -
Measurement of outcomes (Prospective ob-
servational studies)
Unclear risk -
Incomplete outcome data / missing data
(All studies)
Low risk 4 participants withdrew/died/were lost to follow-up but
were still included in analysis for primary endpoint as the
lesion had healed at the last assessment
Selective reporting (All studies) Low risk Reported all expected outcomes
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BURULICO Study 2010 (Continued)
Other bias Low risk 3 cases not laboratory-confirmed, but only a small num-
ber.
Chauty 2007
Methods Prospective observational study
Participants Inclusion criteria: clinical diagnosis of BU; residing in an endemic area
(exclusion criteria: pregnancy; receiving traditional treatment at the time of diagnosis;
history of leprosy, TB; liver, kidney, or hearing problems)
Enrolled: 310participants; 36 immediate surgical excision at another centre, 3 pregnancy,
47 refusals; 224 analysed
Participant characteristics: among the 310 eligible participants, 145 males, 47%; < 15
years, 179 participants (58%), 15 to 49 years, 90 participants (29%), ≥ 50 years, 41
participants (13%)
Lesion types: ulcer 168 (73.8%), of which 29 (18.4%) were < 5 cm, 76 (48.1%) were 4
to 14 cm, and 63 (39.9%) were ≥ 10 cm; non-ulcer 56 (26.2%)
WHO category: N/A
Interventions 8 weeks of rifampicin (10 mg/kg/day) + streptomycin (15 mg/kg/day) was administered
to all participants. During the 4-week assessment, participants who were considered
unlikely to be cured by antibiotics alone (opinion of the treating physician) underwent
surgery
Local dressings were provided for participants with ulcerative lesions. Participants were
treated daily under the direct observation of the clinic nurse either as an outpatient or
inpatient. The study physician evaluated participants every 2 weeks during treatment
Surgery: when indicated
Follow-up period: 1 year after treatment completion
Outcomes 1. Successful treatment: completely healed
2. Recurrence: reactivation of the disease within 1 year after apparent success upon
treatment completion
Standardized outcome: probable cure
Notes Trial location: Benin
Enrolment dates: January 2003 to December 2004
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (Trials) High risk -
Allocation concealment (Trials) High risk -
Blinding of participants and personnel
(Trials)
High risk -
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Chauty 2007 (Continued)
Blinding of outcome assessment (Trials) High risk -
Selection of participants into the study
(Prospective observational studies)
High risk 86/310 patients (28%) who were eligible for the study
were not included; 3 pregnancies, 36 immediate sur-
gical excisions at another centre, 6 participants’ de-
cision to receive traditional treatment, 41 refusals of
antibiotic and/or surgical treatment
Measurement of outcomes (Prospective ob-
servational studies)
Low risk Objective outcome measure (healing)
Incomplete outcome data / missing data
(All studies)
High risk We do not have data for 17 participants who were lost
to follow-up at week 8
Selective reporting (All studies) Low risk Reported all expected outcomes
Other bias High risk Laboratory exam was attempted in 145 of the 168
participants. 40/145 (28%) were negative for both
PCR and smear, indicating that some cases may not
have been BU
Chauty 2011
Methods Prospective observational study
Participants Inclusion criteria: clinically + laboratory-confirmed BU; at least 5 years of age, presented
with lesions ≤ 10 cm in diameter that had appeared within the past 6 months, agreed
to be hospitalized during treatment, and were likely to be followed up for 18 months
(exclusion criteria: multiple lesions, lesions located over a joint, history of treatment
with antimycobacterial drugs, receipt of macrolide or quinolone antibiotics during the
previous month, allergy to rifampicin or clarithromycin, pregnancy, or HIV infection)
Laboratory confirmation: IS2404 dry-reagent-based PCR
Enrolled: 30 participants for analysis
Participant characteristics: 12 males, 40%; 11 were > 15 years of age
Lesion types: ulcer 21 (47%), non-ulcer 9 (30%)
WHO category I: 13 (43%), category II: 17 (57%)
Interventions Rifampicin (10 mg/kg/d) + clarithromycin (12 mg/kg/d), 8 weeks
Surgery: when indicated
Follow-up: participants were hospitalized during treatment for daily direct observation
by nursing staff and were examined by a doctor every week. Swabs or aspiration samples
were collected atweek 4, 6, 8 if the lesionhadnot healed for culture andPCR. Participants
were discharged from hospital when healed and were followed up every 3 months up to
18 months after start of treatment
Outcomes 1. Wound healing at 12 months, without recurrence 18 months after initiation of
antibiotics
2. Need of additional care to antibiotics (limited surgery, excision and skin grafting)
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Chauty 2011 (Continued)
Standarized outcome: cure
Notes Trial location: Benin
Enrolment dates: December 2007 to February 2009
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (Trials) High risk -
Allocation concealment (Trials) High risk -
Blinding of participants and personnel
(Trials)
High risk -
Blinding of outcome assessment (Trials) High risk -
Selection of participants into the study
(Prospective observational studies)
High risk 2/3 of eligible population refused participation due to
refusal of hospitalization
Measurement of outcomes (Prospective ob-
servational studies)
Low risk Objective outcome measure (healing)
Incomplete outcome data / missing data
(All studies)
Low risk No missing data
Selective reporting (All studies) Low risk Reported all expected outcomes
Other bias Low risk No other bias identified.
Espey 2002
Methods Randomized controlled trial
Participants Inclusion criteria: clinical diagnosis of BU*; aged 4 years or older (excluded: history of
TB, leprosy, HIV, liver disease, pregnancy, breastfeeding)
Case definition: the presence of a painless or minimally painful cutaneous ulcer with
undermined margins
Enrolled: 41 participants; 10 participants were lost to follow-up, 1 pregnancy: 30 par-
ticipants for analysis
Participant characteristics: intervention group 11 (73%) males, median 13 years old
(range, 5 to 60); control group 7 (47%) males, median 10 years old (range, 5 to 60)
Lesion types: ulcer 30 (100%)
WHO category: N/A
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Espey 2002 (Continued)
Interventions 1. Dapsone (1.0 to 1.5 mg/kg/day) + rifampicin (10 to 20 mg/kg/day), 2 months
2. Placebo identical in appearance to dapsone, 2 months
Both groups received supportive local ulcer care consisting of cleansing and non-surgical
debridement
Surgery: none
Follow-up: 2 months; photographs were taken at enrolment and at 2 months for 28
participants
Outcomes 1. Clinical change, judged by photographs as “worse”, “unchanged”, or “improved”,
by 2 specialists blinded to group
2. Change in ulcer size
3. Adverse effects
Notes Trial location: Côte d’Ivoire
Enrolment dates: 3 March to 4 April 1994
*Diagnostic tests: not all cases were confirmed as BU: 6/41 (14.6%) skin biopsies were
diagnostic of BU (containing AFB or active necrosis of adipose tissue); 29 (70.7%) were
indicative of BU (granulomatous changes and necrosis, without AFB); the remaining 3
revealed non-specific inflammation; 3/41 (7%) yielded positive cultures
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (Trials) Low risk Quote: “Participants were randomized by lot to one of
two groups.”
Allocation concealment (Trials) Unclear risk No information on allocation concealment
Blinding of participants and personnel
(Trials)
Low risk It does not seem that participants were blinded fully, as
the placebo participants received only 1 pill, whereas the
treatment group participants received 2 pills. Investiga-
tors were also not blinded. However, outcome is proba-
bly unlikely to be influenced by lack of blinding
Blinding of outcome assessment (Trials) High risk Investigators not blinded to treatment status, and out-
come is likely to have been affected by lack of blinding
Selection of participants into the study
(Prospective observational studies)
Unclear risk -
Measurement of outcomes (Prospective ob-
servational studies)
Unclear risk -
Incomplete outcome data / missing data
(All studies)
High risk 10 participants were lost to follow-up with no reasons
provided. Given this study’s sample size, this is a rel-
atively large amount of missing data. The numbers in
each group were initially balanced across treatment and
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Espey 2002 (Continued)
placebo groups
Selective reporting (All studies) Low risk Reported all expected outcomes
Other bias High risk There is a big difference in initial median ulcer size be-
tween treatment and placebo groups
Photography outcome is prone to subjectivity.
A total of 41 skin biopsies from 30 enrolled participants
were taken. 3/30 (10%) yielded no specific change com-
patible to BU, indicating these cases may not be BU
Etuaful 2005
Methods Randomized controlled trial
Participants Inclusion criteria: clinically + laboratory-confirmed BU; had a single nodule or plaque
≤ 10 cm in maximum diameter; aged 15 years or older (exclusion criteria: pregnancy,
treatment with antibiotics, history of leprosy, TB, liver, kidney, or hearing problems)
Laboratory confirmation: either 1 or 2
1. Culture (+) or definite histopathology (the presence of Buruli-type coagulative
necrosis of the dermis or subcuticular issue, with or without granulomas, and with or
without AFB)
2. PCR (+) plus possible histopathology (the presence of panniculitis, with or
without granulomas but without Buruli-type coagulative necrosis) or visible AFB
Enrolled: 33 participants; 1 participant withdrew, 1 excluded, 1 resolved completely
during treatment, 9 participants did not meet final laboratory diagnosis; 21 participants
for analysis
Participant characteristics: 7 male, 33%; mean age N/A
Lesion types: 14 nodules, 7 plaques
WHO category: N/A
Interventions 5-arm study comparing immediate excision of the lesion and closure of the wound (no
antibiotic), rifampicin (10 mg/kg/d) + streptomycin (15 mg/kg/d) given for 4 weeks, 8
weeks, 12 weeks before excision of the lesion
Additional arm added during the study of rifampicin (10 mg/kg/d) + streptomycin (15
mg/kg/d), 2 weeks before excision of the lesion
All participants were admitted to hospital for directly observed therapy
Surgery: all cases
Follow-up period: 12 months after surgery
Outcomes 1. Change in mean surface areas of lesions before and after treatment with
antibiotics for 2, 4, 8, or 12 weeks
2. Recurrence
3. Adverse effects
Notes Trial location: Ghana
Enrolment dates: September 2001 to December 2002
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Etuaful 2005 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (Trials) High risk Participants in 4 groups (4 week, 8 week, 12 week, and
surgery only) were randomized using computer-gener-
ated numbers. Participants in 2 week treatment group
were recruited sequentially and were not randomized
Allocation concealment (Trials) Unclear risk No information on allocation concealment
Blinding of participants and personnel
(Trials)
Low risk Blinding was not possible given different lengths of treat-
ment and surgical intervention, however outcome is un-
likely to be influenced by lack of blinding
Blinding of outcome assessment (Trials) Unclear risk No information on blinding of assessors, and outcome
may be affected by lack of blinding
Selection of participants into the study
(Prospective observational studies)
Unclear risk -
Measurement of outcomes (Prospective ob-
servational studies)
Unclear risk -
Incomplete outcome data / missing data
(All studies)
Low risk All 21 participants eligible for analysis in the study were
analysed
Selective reporting (All studies) Low risk Reported all expected outcomes
Other bias Low risk No other bias identified.
Fehr 1994
Methods Randomized controlled trial
Participants Inclusion criteria: clinically + laboratory-confirmed BU (exclusion criteria: none stated)
Laboratory confirmation: diagnosis of BU was confirmed by ZN staining in 6 partici-
pants, culture in 4 participants, and histopathology in the remaining participants
Enrolled: 18 participants; 6 excluded from analysis due to lost to follow-up (4) and death
(2); 12 participants for analysis
Participant characteristics: 5 male, 42%; sulfamethoxazole/trimethoprim group: 18.3
years (5 to 32), placebo: 20.8 years (8 to 45)
Lesion types: ulcer 12/12 (100%)
1. 4/6 (66%) in the sulfamethoxazole/trimethoprim and 2/6 (33%) in the placebo
group received surgery prior to intervention.
2. Initial ulcer size was 73.8 (9 to 247) cm2 for the sulfamethoxazole/trimethoprim
and 38.7 (15 to 80) cm2 for the placebo group.
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Fehr 1994 (Continued)
Interventions 1. Sulfamethoxazole/trimethoprim (800 mg sulfamethoxazole/160 mg
trimethoprim) 1 tablet twice daily for participants above 12 years; 0.5 tablet twice daily
for younger participants
2. Identical placebo
Surgery: when indicated
Follow-up: follow-up was done by standardized examination including photographic
documentation of ulcer size by the same observer up to 5 times in approximately 2-
weekly intervals
Outcomes 1. Percentage change of ulcer size* at study end
2. Percentage covered by granulation tissue at study end
3. Excision during follow-up
*Ulcer size: calculated by multiplying the greatest width by the greatest depth in cen-
timetres
The study was concluded whenever further excision became necessary during follow-up
Notes Trial location: Ghana
Enrolment dates: February to June 1988
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (Trials) High risk Used alternate allocation method
Allocation concealment (Trials) Unclear risk Unclear statement: “Patients were, in double-blinded
fashion, alternately allocated to Batrium forte or identi-
cal placebo.”
Blinding of participants and personnel
(Trials)
Low risk Identical placebo was used.
Blinding of outcome assessment (Trials) Unclear risk Not explicitly stated that the outcome assessor was
blinded, though outcome was assessed by 1 individual
Selection of participants into the study
(Prospective observational studies)
Unclear risk -
Measurement of outcomes (Prospective ob-
servational studies)
Unclear risk -
Incomplete outcome data / missing data
(All studies)
Low risk Proportion of missing data is relatively large considering
the sample size. However, reasons for exclusions/missing
data are relatively well balanced or unlikely to be related
to true outcome
Selective reporting (All studies) Low risk Reported all expected outcomes
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Fehr 1994 (Continued)
Other bias High risk Baseline characteristics are not well balanced. No signifi-
cant differences, but the groups are so small the P values
would not detect significant differences
Friedman 2016
Methods Prospective observational study
Participants Inclusion criteria: clinically + laboratory confirmed; treated with antimicrobials alone or
with limited surgical debridement* (excluded: those who underwent extensive surgery**)
*Curettage of the lesion or a minor excision to remove excess granulation tissue and to
debride ulcer margins, with or without use of a split skin graft
**Complete excision of the entire lesion including margins of non-necrotic tissue, with
either direct closure or the use of a split skin graft or a vascularized skin and tissue flap
for reconstruction or to cover the defect
Laboratory confirmation: any of (1) a culture ofMycobacterium ulcerans from the lesion,
(2) PCR(+), or (3) histopathology showing a necrotic granulomatous ulcer with the
presence of AFB
Enrolled: 160 participants; 28 underwent extensive surgery and were excluded; 132
participants for analysis
Participant characteristics: 75 males, 56.8%; median age 49 years (range, 1 to 95)
Lesion types: ulcer 110 (83.3%), nodule 9 (6.8%), oedema 10 (7.6%), plaque 3 (2.3%)
WHO category I: 104 (78.8%), category II: 19 (14.4%), category III: 9 (6.8%)
Interventions Antibiotics alone or antibiotics with limited surgical debridement
Included regimens:
Rifampicin (10 mg/kg/d) plus
• Ciprofloxacin (500 mg twice daily)
• Clarithromycin (500 mg twice daily; 7.5 to 15 mg/kg/daily in divided doses in
children)
• Moxifloxacin (400 mg daily)
Surgery: when indicated
Follow-up: 12 months
Outcomes 1. Treatment success defined as complete healing of theM ulcerans lesion without
recurrence within 12 months of treatment commencement (cure)
2. Recurrence
3. Treatment failure
4. Adverse effects
5. Paradoxical reactions
6. Duration of antibiotic administration
Notes Trial location: Australia
Enrolment dates: 1 October 2010 to 31 December 2014
13/132 participants (9.5%) had diabetes mellitus.
Risk of bias
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Friedman 2016 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (Trials) High risk -
Allocation concealment (Trials) High risk -
Blinding of participants and personnel
(Trials)
High risk -
Blinding of outcome assessment (Trials) High risk -
Selection of participants into the study
(Prospective observational studies)
Low risk All patients who met the study inclusion criteria were
included
Measurement of outcomes (Prospective ob-
servational studies)
Low risk Objective outcome measure (healing)
Incomplete outcome data / missing data
(All studies)
Low risk No missing data
Selective reporting (All studies) Low risk Reported all expected outcomes
Other bias Unclear risk 9.5% of participants had comorbidities that may have
affected healing rate and time
Kibadi 2010
Methods Prospective observational study
Participants Inclusion criteria: clinically diagnosed BU; ulcerative lesions with maximum diameter
≥ 10 cm; 3 to 75 years old; residence in an endemic area (exclusion criteria: previous
treatment by rifampicin or streptomycin; previous diagnosis of leprosy or TB; pregnancy;
presence of cardiovascular, hepatic, or renal disease)
Enrolled: 94 participants; 1 refusal, 1 lost to follow-up; 92 participants for analysis
Participant characteristics: 43 males, 47%; 38 participants ≤ 15 years, 43 participants
15 to 49 years, 11 participants ≥ 50 years
Lesion types: ulcer 92 participants (100%)
WHO category II: 90 participants (97.8%), category III: 2 participants (2.2%)
Interventions Rifampicin (10 mg/kg/d) + streptomycin (15 mg/kg/d) for 12 weeks, with surgery after
the first 4 weeks
Local treatment was applied daily with an aqueous solution of chloramine-metronida-
zole-nitrofurandoine
Surgery: all cases
Follow-up period: follow-up evaluation was carried out at the end of the 4th and 12th
week of treatment. Recurrence was followed up for at least 2 years after treatment com-
pletion
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Kibadi 2010 (Continued)
Outcomes 1. Clinical outcome: “success” (4th week: 10% to 30% reduction in ulcer size and/or
absence of new necrotic tissue, 12th week: healed), “clinical status quo” (no change in
the size or presence of necrotic tissue), or “failure” (increase in the size and presence of
new necrotic tissue)
2. Recurrence: reappearance of an ulcer or another form of the disease (nodule,
papule, plaque, oedema, or bone involvement) at the original site of the lesion or
elsewhere
Standardized outcome: cure
Notes Trial location: Democratic Republic of Congo
Enrolment dates: October 2006 to September 2007
Clinical outcome was compared between PCR(+) and PCR(-) participants
PCR(+): 61 participants
PCR(-): 31 participants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (Trials) High risk -
Allocation concealment (Trials) High risk -
Blinding of participants and personnel
(Trials)
High risk -
Blinding of outcome assessment (Trials) High risk -
Selection of participants into the study
(Prospective observational studies)
Low risk Selection not related to intervention or outcome.
Measurement of outcomes (Prospective ob-
servational studies)
Low risk Objective outcome measure (healing)
Incomplete outcome data / missing data
(All studies)
Low risk 1 lost to follow-up, 1 death
Selective reporting (All studies) Low risk Reported all expected outcomes
Other bias High risk PCR-negative cases (30 participants, 33%) may not
be BU.
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Lunn 1964
Methods Prospective observational study
Participants Inclusion criteria: individuals with provedmycobacterial ulceration who presented them-
selves for treatment (exclusion criteria: none stated)
Enrolled: 10 participants
Participant characteristics: 6 males, 60%; median age 12.7 years (range, 6 to 20)
Lesion type: ulcers 10/10 (100%)
WHO category: N/A
Interventions B.663 (riminophenazine derivative; currently, clofazimine) was given as part of prepara-
tion for operation for 1 to 4 weeks and continued after operation until healing
Adults > 50 kg: 300 mg/day
Adults 25 to 50 kg, children: 200 mg/day
Surgery: all cases
Follow-up: not specified
Outcomes Healing
Standarized outcome: possible cure
Notes Trial location: Uganda
Enrolment dates: none stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (Trials) High risk -
Allocation concealment (Trials) High risk -
Blinding of participants and personnel
(Trials)
High risk -
Blinding of outcome assessment (Trials) High risk -
Selection of participants into the study
(Prospective observational studies)
Low risk Selection not related to intervention or outcome.
Measurement of outcomes (Prospective ob-
servational studies)
Low risk Objective outcome measure (healing)
Incomplete outcome data / missing data
(All studies)
Unclear risk Not clear at what time point participants were assessed
and whether they had data for all 10 participants at a
given time point
Selective reporting (All studies) Unclear risk No predefined outcomes
Other bias Unclear risk No laboratory confirmation
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O’Brien 2012
Methods Prospective observational study
Participants Inclusion criteria: clinically + laboratory-confirmedBU;managedwith surgery (exclusion
criteria: none stated)
Laboratory confirmation: any of (1) a culture ofMycobacterium ulcerans from the lesion,
(2) PCR(+), or (3) histopathology showing a necrotic granulomatous ulcer with the
presence of AFB
Enrolled: 147 participants; 1 without surgery, 2 deaths, 1 lost to follow-up, 10 ongoing
treatment were excluded; 137 lesions of 133 participants analysed
Participant characteristics: 67 males, 50.4%; median age 62 years (range, 3 to 94)
Lesion types: clinical type of lesion was recorded in 122/133 participants (92%); ulcer
106 (87%), nodules 9 (7%), oedematous lesion 7 (6%)
WHO classification: N/A
Interventions Surgery with or without different oral antibiotic treatments
90 participants received antibiotics as follows.
• Rifampicin + ciprofloxacin (55 participants, 61%)
• Rifampicin + clarithromycin (21 participants, 23%)
• Rifampicin + clarithromycin, and ethambutol (5 participants, 4%)
• Ciprofloxacin + clarithromycin (4 participants, 4%)
• Rifampicin + moxifloxacin (2 participants, 2%)
• Clarithromycin + ethambutol (1 participant, 1%)
• Rifampicin + ethambutol, and amikacin (1 participant, 1%)
• Clarithromycin only (1 participant, 1%)
Drug dosages:
• Rifamipicin 10 mg/kg/day (up to a maximum of 600 mg/day)
• Ciprofloxacin 500 mg twice daily
• Clarithromycin 500 mg twice daily
• Moxifloxacin 400 mg daily
• Amikacin 15 mg/kg/day
• Ethambutol not given
Surgery: all cases
Follow-up: 12 months
Outcomes 1. Treatment success, defined as complete healing of theM ulcerans lesion without
recurrence within 12 months of treatment commencement (cure)
2. Recurrence
3. Antibiotic duration prior to surgery
4. Adverse effects
5. Paradoxical reactions
Notes Trial location: Australia
Enrolment dates: March 1998 to May 2010
11 participants were complicated with diabetes mellitus, 5 with malignancy, 4 with
connective tissue disease, and 4 with immunosuppressive treatment
Risk of bias
Bias Authors’ judgement Support for judgement
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O’Brien 2012 (Continued)
Random sequence generation (Trials) High risk -
Allocation concealment (Trials) High risk -
Blinding of participants and personnel
(Trials)
High risk -
Blinding of outcome assessment (Trials) High risk -
Selection of participants into the study
(Prospective observational studies)
High risk Small numbers lost to follow-up, but 10were excluded
because treatment was ongoing, therefore selection
related to outcome present
Measurement of outcomes (Prospective ob-
servational studies)
Low risk Outcomes were objective.
Incomplete outcome data / missing data
(All studies)
Low risk No missing data
Selective reporting (All studies) Low risk Reported all expected outcomes
Other bias High risk The proportion of participants receiving antibiotic
treatment increased from 2005; there might be im-
portant differences between groups especially before
this time. Study not really able to detect differences
between treatment + surgery and surgery alone. 24/
133 (18%) of participants had comorbidities thatmay
have affected healing
O’Brien 2013b
Methods Prospective observational study
Participants Inclusion criteria: clinically + laboratory-confirmed BU; received antibiotics with or
without surgery (exclusion criteria: none stated)
Laboratory confirmation: any of (1) a culture ofMycobacterium ulcerans from the lesion,
(2) PCR(+), or (3) histopathology showing a necrotic granulomatous ulcer with the
presence of AFB
Enrolled: 160 participants; 2 deaths, 2 lost to follow-up; 156 participants analysed
Participant characteristics: 86 males, 55.1%; 13 participants (8.3%) < 15 years, 62
participants (39.7%) 15 to 59 years, 81 participants (51.9%) > 60 years
Lesion types: ulcer 137 (87.8%), nodules 10 (6.4%), oedematous lesion 9 (5.8%)
WHO classification: N/A
Interventions Different oral antibiotic treatments.
Participants received combinations of the following.
• Rifampicin 147 (94.2%)
• Ciprofloxacin 101 (64.7%)
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O’Brien 2013b (Continued)
• Clarithromycin 48 (30.8%)
• Ethambutol 11 (7.1%)
• Amikacin 5 (3.2%)
• Moxifloxacin 2 (1.5%)
Drug dosages
• Rifamipicin 10 mg/kg/day (up to a maximum of 600 mg/day)
• Ciprofloxacin 500 mg twice daily
• Clarithromycin 7.5 mg/kg/twice daily (up to maximum of 500 mg twice daily)
• Moxifloxacin 400 mg daily
• Amikacin 15 mg/kg/day
Surgery: when indicated
Follow-up: at least 12 months
Outcomes 1. Episodes of paradoxical reactions
2. Lesion site
3. Diagnosis and treatment
4. Healing of paradoxical reactions
5. Predictors of paradoxical reactions
Notes Trial location: Australia
Enrolment dates: 1 January 1998 to 31 December 2011
13 (8.3%) participants were complicated with diabetes mellitus and 11 (7.1%) with
immune suppression (defined as current treatment with immunosuppressive medication
(for example, prednisolone) or an active malignancy)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (Trials) High risk -
Allocation concealment (Trials) High risk -
Blinding of participants and personnel
(Trials)
High risk -
Blinding of outcome assessment (Trials) High risk -
Selection of participants into the study
(Prospective observational studies)
Low risk Small number (4) not included as did not have 12
months follow-up or had died
Measurement of outcomes (Prospective ob-
servational studies)
Low risk Paradoxical reaction clearly defined.
Incomplete outcome data / missing data
(All studies)
Low risk No missing data
Selective reporting (All studies) Low risk Reported all expected outcomes
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O’Brien 2013b (Continued)
Other bias Low risk No other bias identified.
Phillips 2014a
Methods Prospective observational study
Participants Inclusion criteria: clinically + laboratory-confirmed BU; at least 5 years of age, presented
with lesions ≤ 15 cm in diameter
(exclusion criteria: tuberculosis or leprosy; renal or hepatic impairment, auditory prob-
lems; under treatment with antibiotics or herbal preparations; pregnancy)
Laboratory confirmation: IS2404 dry-reagent-based PCR
Enrolled: 82 patients screened for BU; 17 not meeting clinical and or epidemiological
criteria for BU, 18 large category III lesions, 1 pregnancy, 3 were below 5 years; 43 for
analysis
Participant characteristics: 18 males, 42%; median age 15 (range, 5 to 70)
Lesion types: ulcer 20 (47%), nodules 14 (32%), plaque 9 (21%)
WHO category I: 27 (63%), category II: 12 (28%), category III: 4 (9%)
Interventions Rifampicin (10 mg/kg/d) + streptomycin (15 mg/kg/d), 2 weeks followed by rifampicin
(10 mg/kg/d) + clarithromycin (7.5 mg/kg/d), 6 weeks
The treatment was administered under the direct observation of village health workers
Surgery: when indicated; surgery and skin grafting was offered to participants whose
lesion had enlarged during or after treatment by more than 150% of the initial size or
had not healed by week 52
Follow-up: 52 weeks
Outcomes 1. Healing of theMycobacterium ulcerans lesion without recurrence within 12
months of treatment commencement (cure)
2. Healing time
3. Recurrence
4. Adverse event (vestibulocochlear toxicity)
5. Paradoxical reactions
Notes Trial location: Ghana
Enrolment dates: July 2009 to July 2010
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (Trials) High risk -
Allocation concealment (Trials) High risk -
Blinding of participants and personnel
(Trials)
High risk -
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Phillips 2014a (Continued)
Blinding of outcome assessment (Trials) High risk -
Selection of participants into the study
(Prospective observational studies)
Low risk Selection not related to intervention or outcome.
Measurement of outcomes (Prospective ob-
servational studies)
Low risk Objective outcome measures
Incomplete outcome data / missing data
(All studies)
Low risk Only 2 (5%) participants were lost to follow-up.
Selective reporting (All studies) Low risk Reported all expected outcomes
Other bias Low risk No other bias identified.
Revill 1973
Methods Randomized controlled trial
Participants Inclusion criteria: clinically diagnosed BU (exclusion criteria: none stated)
Laboratory confirmation: 22/105 (21%) participants had positive cultures forMycobac-
terium ulcerans.
Enrolled: 106 participants; 1 excluded; 105 participants for analysis
Participant characteristics: sex N/A; age N/A
Lesion types: ulcer 34/105 (33%)
WHO category: N/A
Interventions Participants were placed into 4 groups:
1. uncomplicated non-ulcerated lesions with immediate surgery withheld (Group A:
34 participants, 32.5%);
2. uncomplicated non-ulcerated lesions with immediate surgery (Group B: 16
participants, 15%);
3. complicated non-ulcerated lesions with immediate surgery (Group C: 21
participants, 20%);
4. ulcerated lesion with immediate surgery (Group D: 34 participants, 32.5%).
They were randomized to the following groups.
1. Clofazimine (10 to 20 mg/kg/day) continued for at least 1 month after complete
clinical healing (3 to 6 months)
2. Placebo capsule
Surgery: when indicated
Follow-up: participants were followed up every 2 weeks at a clinic in the trial area. Those
who did not attend were visited at home. After the treatment period, participants were
seen at approximately 3-monthly intervals. The follow-up period ranged from 17 to 40
months (median of 32 months)
Outcomes 1. Healing
2. Median healing time
3. Recurrence
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Revill 1973 (Continued)
Standarized outcome: possible cure
Notes Trial location: Uganda
Enrolment dates: July 1968 to March 1970
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (Trials) High risk Only partial group was randomized.
Allocation concealment (Trials) Low risk Allocation concealed from both participant and doctor.
Blinding of participants and personnel
(Trials)
Low risk Placebo capsule was used, and both participant and doc-
tor were blinded
Blinding of outcome assessment (Trials) Unclear risk No information about whether outcome assessors were
blinded
Selection of participants into the study
(Prospective observational studies)
Unclear risk -
Measurement of outcomes (Prospective ob-
servational studies)
Unclear risk -
Incomplete outcome data / missing data
(All studies)
Low risk Only 1 participant missing, and reason explained and
unlikely to affect outcome
Selective reporting (All studies) Low risk Reported all expected outcomes
Other bias Low risk No other bias identified.
Sarfo 2010
Methods Prospective observational study
Participants Inclusion criteria: clinically + laboratory-confirmed BU (exclusion criteria: previous di-
agnosis of leprosy or TB; presence of renal or hepatic impairment or auditory problems;
treatment with antibiotics or herbal preparations)
Laboratory confirmation: diagnosis was confirmed by 1 or more methods. Swabs, punch
biopsy specimen, or fine-needle aspirates were taken to test for the following
1. AFB
2. Culture for Mycobacterium ulcerans
3. PCR for IS2404
Enrolled: 171 participants; 6 participants with no diagnostic samples, 5 participants with
negative laboratory results; 160 participants for analysis
Participant characteristics: 66 males (41%), median 12 years (range, 1 to 75 years)
Lesion types: ulcer 86 (53.7%), nodule 36 (22.5%), plaque 14 (8.8%), oedema 24 (15%)
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Sarfo 2010 (Continued)
WHO category I: 48 (30%), category II: 56 (35%), category III: 56 (35%)
Interventions Rifampicin (10 mg/kg/d) + streptomycin (15 mg/kg/d) for 8 weeks
Surgery: when indicated
Follow-up period: 1 year after treatment completion
Outcomes 1. Healing of theM ulcerans lesion without recurrence within 12 months of
treatment commencement (cure)
2. Healing time
3. Rate of healing of each measurable lesion
4. Recurrence until 12 months
5. Adverse effects
6. Paradoxical reactions
Notes Trial location: Ghana
Enrolment dates: September 2005 to December 2007
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (Trials) High risk -
Allocation concealment (Trials) High risk -
Blinding of participants and personnel
(Trials)
High risk -
Blinding of outcome assessment (Trials) High risk -
Selection of participants into the study
(Prospective observational studies)
Low risk Selection not related to intervention or outcome.
Measurement of outcomes (Prospective ob-
servational studies)
Low risk Objective outcome measures
Incomplete outcome data / missing data
(All studies)
Low risk 1 death and 1 lost to follow-up at 1 year
Selective reporting (All studies) Low risk Reported all expected outcomes
Other bias Low risk No other bias identified.
Abbreviations: AFB: acid-fast bacilli; BU: Buruli ulcer; IQR: interquartile range; N/A: not available; PCR: polymerase chain reaction;
SD: standard deviation; TB: tuberculosis; WHO: World Health Organization; ZN: Ziehl-Neelsen.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Addison 2015 Conference proceeding
Adjei 1998 Wrong study design
Adou 2009 Review
Adu 2011 Wrong study design
Adu 2015 Wrong study design
Aguiar 1997 Wrong study design
Alferink 2013 Wrong study design
Alffenaar 2010 Duplicate
Anonymous 2010 Review
Arens 2015 Conference proceeding
Azanmasso 2013 Wrong outcomes
Bamberger 2011 Review
Barogui 2009 Wrong study design
Barogui 2013 Wrong study design
Cornet 1992 Wrong study design
Cowan 2015 Wrong study design
Darie 1993 Wrong study design
de Bergeyck 1980 Wrong study design
Debacker 2005 Wrong study design
Friedman 2012 Wrong intervention
Gordon 2010 Wrong study design
Guerra 2008 Wrong study design
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(Continued)
Josse 1994 Wrong study design
Kanga 2003 Wrong study design
Kibadi 2007 Wrong study design
Klis 2014a Duplicate
Klis 2014b Commentary
Klis 2014c Duplicate
Klis 2014d Commentary
Klis 2016 Wrong study design
Kotey 2011 Conference proceeding
Lunn 1965 Review
Marion 2015 Wrong study design
Milánkovits 2010 Commentary
Mou 2015 Wrong outcomes
Nienhuis 2012 Duplicate
O’Brien 2014 Wrong intervention
Oluwasanmi 1975 Wrong study design
Pfau 2015 Conference proceeding
Phanzu 2006 Wrong study design
Phanzu 2011 Wrong study design
Phillips 2004 Wrong intervention
Phillips 2014b Commentary
Ruf 2011 Wrong study design
Ruf 2015 Wrong intervention
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(Continued)
Saka 2013 Wrong study design
Schunk 2009 Wrong study design
Schütte 2009 Wrong setting
Stienstra 2012 Wrong study design
Teelken 2003 Wrong study design
van der Werf 1989 Wrong study design
Vignier 2014 Wrong study design
Vuagnat 2011 Wrong intervention
Yeboah-Manu 2013 Conference proceeding
Characteristics of ongoing studies [ordered by study ID]
NCT01432925
Trial name or title Timing of surgical intervention in Buruli ulcer patients treated with antibiotics (Burulitime)
Methods Randomized controlled trial (single-blind)
Participants Inclusion criteria: aged 3 years and older, all stages of the BU disease with confirmation by direct microscopy
following acid-fast staining or PCR
Exclusion criteria: patients not on the standard treatment of 8 weeks of rifampicin and streptomycin for
any reason, including non-compliant patients; treatment with macrolide or quinolone antibiotics, or antitu-
berculous medication, or immunomodulatory drugs including corticosteroids within the previous 1 month;
contraindication for general anaesthesia; pregnancy; osteomyelitis; lesion close to the eye; refusal to surgery
at any point in the intended treatment; HIV positive; lack of willingness to give informed consent
Estimated enrolment: 260
Interventions 1. Rifampicin (10 mg/kg/d) + streptomycin (15 mg/kg/d), 8 weeks plus surgery at week 8
2. Rifampicin (10 mg/kg/d) + streptomycin (15 mg/kg/d), 8 weeks plus surgery at week 14
Outcomes Primary outcome
1. Healing without surgical intervention (time frame: 1 year)
Secondary outcomes
1. Extent of surgery by measurement of lesional size
2. Functional limitations after the end of treatment and 1 year after the start of treatment
3. Duration of admission
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NCT01432925 (Continued)
Starting date September 2011
Anticipated end date: January 2017
Contact information Ymkje Stienstra, MD PhD, University Medical Center Groningen
Notes Trial location: Benin
Registration number: NCT01432925
NCT01659437
Trial name or title Randomized controlled trial comparing efficacy of 8 weeks treatment with clarithromycin and rifampicin
versus streptomycin and rifampicin for Buruli ulcer (Mycobacterium ulcerans infection)
Methods Randomized controlled trial (multicentre, open-label)
Participants Inclusion criteria: aged 5 years and older, with a clinical diagnosis of BU disease (categories I and II, cross-
sectional diameter ≤ 10 cm) as agreed by study site treatment team led by the lead clinicians
Exclusion criteria: lesion sizes > 10 cm in cross-sectional diameter; children < 5 years, or < 20 kg body weight;
pregnancy; previous treatment of Buruli ulcer, tuberculosis, or leprosy with at least 1 of the study drugs
(rifampicin, streptomycin, clarithromycin); history of hypersensitivity to rifampicin and/or streptomycin and/
or clarithromycin; previous treatmentwithmacrolide or quinolone antibiotics, or antituberculosismedication,
or immunomodulatory drugs including corticosteroids within 1 month; current treatment with any drugs
likely to interact with the study medication; co-infection with HIV; history or having current clinical signs
of ascites, jaundice, partial or complete deafness, myasthenia gravis, renal dysfunction (known or suspected)
, diabetes mellitus, and severe immune compromise (for example, immunosuppressive drugs after organ
transplant), or evidence of (previous) tuberculosis, Buruli ulcer or leprosy, or terminal illness (for example,
metastasized cancer); unable to take oral medication or having gastrointestinal disease likely to interfere
with drug absorption; individuals with known or suspected bowel strictures who cannot tolerate macrolide
antibiotics such as clarithromycin; mental condition likely to interfere with ability to comply with the study
protocol
Estimated enrolment: 415
Interventions 1. Rifampicin (10 mg/kg/d) + streptomycin (15 mg/kg/d), 8 weeks
2. Rifampicin (10 mg/kg/d) + clarithromycin (7.5 mg/kg/d), 8 weeks
Outcomes Primary outcome
1. Healing without recurrence and without excision surgery (time frame: 12 months after start of
treatment)
Secondary outcomes
1. Recurrence rate within 12 months of treatment initiation
2. Number of recurrent lesions occurring after initial healing within 12 months of treatment initiation
3. Rate of treatment failure within 12 months of treatment initiation
4. Rate of paradoxical response within 12 months of treatment initiation
5. Proportion of participants with reduction in lesion surface area within 12 months of treatment
initiation
6. Time taken for complete lesion healing within 12 months of treatment initiation
7. Proportion (%) of participants with complete healing without additional surgery or relapse
8. Interval between healing and recurrence
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NCT01659437 (Continued)
9. Proportion of each type of surgery within 12 months of treatment initiation
10. Time from treatment initiation to surgery if any
11. Proportion of participants with residual functional limitations
12. Treatment discontinuation and compliance rates
13. Incidence of all adverse effects within 12 months of treatment initiation
Starting date December 2012
Anticipated end date: January 2018
Contact information Tjip S van der Werf, Professor, University Medical Center Groningen (t.s.van.der.werf@umcg.nl)
Notes Trial location: 1 centre in Benin and 4 centres in Ghana
Registration number: NCT01659437
Abbreviations: BU: Buruli ulcer; PCR: polymerase chain reaction
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D A T A A N D A N A L Y S E S
Comparison 1. Rifampicin combined with streptomycin versus surgery alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Recurrence 1 21 Risk Ratio (M-H, Fixed, 95% CI) 0.12 [0.01, 2.51]
Comparison 2. Rifampicin combined with clarithromycin versus rifampicin combined with streptomycin in the
consolidation phase
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cure 1 151 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.87, 1.03]
2 Recurrence at 12 months 1 151 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
A D D I T I O N A L T A B L E S
Table 1. Monotherapy for treating Buruli ulcer: description of studies and main results
Regi-
men
Study De-
sign
Com-
par-
isons
Surgery
Inclu-
sion
crite-
ria
(age,
le-
sion)
Labo-
ratory
(Y/N)
N Sex
(M:F)
Age Le-
sion
types
Ques-
tion
Out-
come
mea-
sure
and
time
point
(num-
ber
anal-
ysed
if dif-
ferent
from
N)
Re-
sults
Ob-
serva-
tion
CLF Revill
1973
RCT 2
groups:
1. Rx at
least
until
When
indi-
cated
None N 105 NR NR Ul-
cer: 34
(32%)
Non-
ul-
Does
CLF
reduce
recur-
rence
Recur-
rence 1. 8/51
(15.
7%)
No
obvi-
ous ef-
fect
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Table 1. Monotherapy for treating Buruli ulcer: description of studies and main results (Continued)
1
month
after
com-
plete
clini-
cal
heal-
ing (3
to 6
months)
2. Placebo
cer: 71
(68%)
rates? 2. 10/54
(18.
5%)
Is CLF
effec-
tive?
Healed
(n =
34)a
1. 5/13
(38%)
2. 6/21
(29%)
No
obvi-
ous ef-
fect
Does
CLF
shorten
the
heal-
ing
time?
Me-
dian
heal-
ing
time
(n =
25)b
1. 21
weeks
(n = 8)
2. 14
weeks
(n =
17)
No
obvi-
ous ef-
fect
CLF Lunn
1964
POS 1
group:
Rx for
1 to 4
weeks
fol-
lowed
by
surgery
All None N 10 6:4 Mean
12.
7 (5 to
25)
Ulcer:
10
(100%)
What
is the
heal-
ing
rate
for
partic-
ipants
treated
with
CLF
and
surgery?
Healed
6/10
(60%)
Early
study
inves-
tigat-
ing the
pos-
sible
effect
of
treat-
ment
of BU
with
Rx.
Heal-
ing
rate
with
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Table 1. Monotherapy for treating Buruli ulcer: description of studies and main results (Continued)
CLF
plus
surgery
was
60%.
The
sample
size
is too
small
to
draw
any
con-
clu-
sion
from
this
study
TMP/
SMX
Fehr
1994
RCT 2
groups:
1. Rx
until
fur-
ther
exci-
sion
be-
came
neces-
sary
(n =
6)
2. Placebo
(n =
6)
When
indi-
cated
None Y 12 5:7
1. Mean
18.3
(5 to
32)
2. Mean
20.8
(8 to
45)
Ulcer:
12
(100%)
Is
TMP/
SMX
effec-
tive?
%
change
in
ulcer
size at
study
endc,d
1. -
10.9%
(-26%
to -
6%)
2. 24.5%
(-15%
to
166%)
No
obvi-
ous ef-
fect
% cov-
ered
by
granu-
lation
tis-
sue at
study
end
1. 92%
(70%
to
100%)
2. 57%
(0 to
100%)
aHealing was measured in 34 participants with non-ulcerated lesions who were withheld from immediate surgery.
bHealing time was measured in 25 participants with non-ulcerated lesions who were withheld from surgery and had small lesions (< 5
cm in diameter).
c4 participants in group 1 and 2 participants in group 2 had surgery prior to intervention.
d Initial mean ulcer size: (1) 73.8 cm2 (9 to 247), (2) 38.7 cm2 (15 to 80).
Abbreviations: CLF, clofazimine; TMP/SMX, sulfamethoxazole/trimethoprim; Lab, laboratory confirmation; NR, not reported; POS,
prospective observational study; RCT, randomized controlled trial; Rx, treatment.
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Table 2. Rifampicin combined with streptomycin for treating Buruli ulcer: description of studies and main results
Regi-
men
Study De-
sign
Com-
par-
isons
Surgery
Inclu-
sion
(age,
le-
sion)
Labo-
ratory
(Y/N)
N Sex
(M:F)
Age Le-
sion
types
Ques-
tion
Out-
come
mea-
sure
and
time
point
(num-
ber
anal-
ysed if
differ-
ent
from
N)
Re-
sults
Our
obser-
vation
RFP
and
SM
Etua-
ful
2005
RCT 5
groups:
Rx
given
for
2, 4,
8, 12
weeks
prior
to
surgery
versus
surgery
alone
All ≥ 15
years
Non-
ulcer
Size <
10 cm
Y 21 7:14 NR Nod-
ule: 14
(67%)
Plaque:
7
(33%)
Does
RFP
+ SM
before
surgery
reduce
recur-
rence?
Recur-
rence,
12
months
Rx +
surgery:
0/16
Surgery
alone:
1/5
No
obvi-
ous ef-
fect
Does
RFP +
SM re-
duce
lesion
size?
Mean
surface
area
reduc-
tion in
lesion
size
before
and af-
ter Rx
(n =
16)a
2
weeks,
5 par-
tici-
pants:
29%
4
weeks,
3 par-
tici-
pants:
52%
8
weeks,
5 par-
All
tend
to get
smaller
over
time.
No
obvi-
ous
effect
of
longer
treat-
ments
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Table 2. Rifampicin combined with streptomycin for treating Buruli ulcer: description of studies andmain results (Continued)
tici-
pants:
31%
12
weeks,
3 par-
tici-
pants:
41%
RFP
and
SM
Kibadi
2010
POS 1
group:
Rx for
12
weeks
All (at
week
4)
3
to 75
years
Ulcer
Size >
10 cm
N 92 43:49 < 15
years:
38
(41%)
; 15 to
49
years:
43
(47%)
;
≥ 50
years:
11
(12%)
Ulcer:
92
(100%)
Is RFP
+ SM
for 12
weeks
with
surgery
at
week 4
effec-
tive?
Healed
with
Rx +
surgery,
12
weeks
85/92
(92.
4%)b
Surgery
plus
12
weeks
of Rx
asso-
ciated
with
high
heal-
ing
and
low
recur-
rence
at 24
months
in
large
le-
sions.
Inde-
pen-
dent
effect
of
antibi-
otics
not
evalu-
ated
Recur-
rence,
24
months
2/
92 (2.
2%)c
RFP
and
SM
Chauty
2007
POS 1
group:
Rx for
8
weeks
When
indi-
cated
(at
week
4,
None N 224 145:
79
< 15
years:
179
(58%)
;
15 to
Ulcer:
168
(75%)
Non-
ul-
cer: 56
Does
RFP +
SM for
8
weeks
work?
Healed
with
Rx ±
surgery,
after 8
206/
206
(100%)
d
Regi-
men
com-
bined
with
surgery
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Table 2. Rifampicin combined with streptomycin for treating Buruli ulcer: description of studies andmain results (Continued)
week
8)
49
years:
90
(29%)
;
≥ 50
years:
41
(13%)
(26%) weeks
(n =
206)d
as
needed
was
asso-
ciated
with
high
heal-
ing
rate
after 8
weeks
and
low
recur-
rence
at 12
months.
48%
of
partic-
ipants
healed
with
Rx
alone.
52%
re-
quired
surgery
to heal
Healed
with
Rx
alone,
after 8
weeks
(n =
206)d
98/
206
(48%)
e
Un-
der-
went
surgery
(n =
206)d
108/
206
(52%)
f,g
Healed
with
Rx +
surgery,
after 8
weeks
(n =
108)
108/
108
(100%)
Recur-
rence,
12
months
(n =
208)h
3/208
(1.
4%)i
RFP
and
SM
Sarfo
2010
POS 1
group:
Rx for
8
When
indi-
cated
(post-
None Y 160 66:94 Me-
dian
12
Ul-
cer: 86
(54%)
Does
RFP +
SM for
Healed
with
158/
159
(99.
Regi-
men
com-
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Table 2. Rifampicin combined with streptomycin for treating Buruli ulcer: description of studies andmain results (Continued)
weeks Rx; af-
ter
week
8)
years
(1 to
75)
Nod-
ule: 36
(22%)
Plaque:
14
(9%)
Oedema:
24
(15%)
8
weeks
work?
Rx ±
surgery,
12
months
(n =
159)j
3%) bined
with
surgery
as
needed
was
asso-
ciated
with
high
heal-
ing
rate
and
low
recur-
rence
at 12
months.
95%
of
partic-
ipants
healed
with
Rx
alone.
5% re-
quired
surgery
to heal
Healed
with
Rx
alone,
12
months
(n =
159)j
151/
159
(95%)
Un-
der-
went
surgery
(n =
159)j
8/159
(5%)k
Healed
with
Rx +
surgery,
12
months
(n = 8)
7/
8 (87.
5%)l
Recur-
rence,
12
months
(n =
158)m
0/158
(0%)
RFP
and
SM
Adu
2013
POS 1
group:
Rx for
8
weeks
When
indi-
cated
(post-
Rx; af-
None Y 126 64:62 Mean
29.8
years
(1
Ulcer:
116
(92%)
Does
RFP +
SM for
8
Healed
with
Rx
61/
126
(48%)
About
half
(48%)
healed
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Table 2. Rifampicin combined with streptomycin for treating Buruli ulcer: description of studies andmain results (Continued)
ter
week
8)
year 3
months
to 98)
Papule:
1 (0.
5%)
Nod-
ule: 2
(1.
5%)
Oedema:
4(3%)
Osteo:
2 (1.
5%)
Con-
tracure:
2 (1.
5%)
weeks
work?
alone,
8
weeks
with
Rx
alone.
The
other
half
under-
went
surgery
in-
clud-
ing ex-
cision,
skin
graft-
ing,
and
con-
trac-
ture
release
RFP
and
SM
Ag-
benorku
2011
POS 1
group:
Rx for
8
weeks
All
(dur-
ing or
post-
Rx)
None Y 189 113:
76
NR Ulcer:
145
(77%)
Nod-
ule: 38
(20%)
Plaque:
6 (3%)
Does
RFP
+ SM
for 8
weeks
with
surgery
work?
Healed
with
Rx +
surgery,
2 years
n
182/
189
(96.
3%)
Surgery
plus 8
weeks
of Rx
was
asso-
ciated
with
high
heal-
ing
rate
and
low
recur-
rence.
Inde-
pen-
dent
effect
of Rx
not
evalu-
ated
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Table 2. Rifampicin combined with streptomycin for treating Buruli ulcer: description of studies andmain results (Continued)
Recur-
rence,
2 years
1/189
(0.
5%)
RFP
and
SM
Beiss-
ner
2015
POS 1
group:
Rx for
8
weeks
When
indi-
cated
(post-
Rx; af-
ter
week
8)
None Y 129 60:69 Me-
dian
10
years
(2 to
68)
Ul-
cer: 73
(57%)
Nod-
ule: 19
(15%)
Plaque:
26
(20%)
Oedema:
11
(8%)
Does
RFP +
SM for
8
weeks
work?
Healed
with
Rx ±
surgery,
> 6
months
109/
129
(84.
5%)o
Regi-
men
com-
bined
with
surgery
as
needed
was
asso-
ciated
with
rela-
tively
high
heal-
ing
rate
and no
recur-
rence
at
mini-
mum
6
months.
70%
of
partic-
ipants
healed
with
Rx
alone.
27%
of
partic-
ipants
re-
quired
surgery,
of
which
54%
healed
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Table 2. Rifampicin combined with streptomycin for treating Buruli ulcer: description of studies andmain results (Continued)
Healed
with
Rx
alone,
> 6
months
90/
129
(69.
8%)
Un-
der-
went
surgery,
> 6
months
35/
129
(27%)
Healed
with
Rx +
surgery,
6
months
(n =
35)
19/35
(54%)
Recur-
rence,
> 6
months
None
a16 participants who received Rx plus surgery were analysed. Participant characteristics for this group were: M:F = 6:10; age: NR;
lesion types: nodule, 11 (69%), plaque, 5 (31%).
bPCR(+) group, 60/61 (98.4%); PCR(-) group, 25/30 (83.3%).
c2/61(3.3%) among PCR(+) group.
d17 lost to follow-up; 1 death.
eUlcer size < 5 cm, 22/98 (22.5%); ulcer size 5 to 14 cm, 40/98 (41%); ulcer size >= 15 cm, 12/98 (12%); non-ulcer, 24/98 (24.5%).
fUlcer size < 5 cm, 5/108 (4.6%); ulcer size 5 to 14 cm, 27/108 (25%); ulcer size >= 15 cm, 46/108 (42.6%); non-ulcer, 30/108
(27.8%).
gDecision to perform surgery was made by a treating physician: immediate upon enrolment, 4/108 (3.7%); 4-week assessment, 83/
108 (76.9%); 8-week assessment, 21/108 (19.4%).
h208 participants were retrieved for 1-year follow-up.
i2 among the Rx-only group; 1 among the Rx + surgery group.
j1 death.
k2 participants with nodules, 1 participant with plaque, 5 participants with ulcerated oedematous lesions, and 2 participants with large
ulcers were offered surgical intervention after 8 weeks of Rx; 8 accepted surgery.
l1 participant evaluated as treatment failure in this review although successful treatment at 1 year follow-up. The participant received
additional 4 weeks of RFP + SM (a total of 12 weeks) with breaking down of skin grafting with culture positive during course of
treatment.
m158 participants were retrieved for 1-year follow-up after treatment completion.
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nDebridement and skin grafting included as surgery: 38 participants (20.1%) with nodules or plaque excised, 151 participants with
ulcers (79.9%) had debridement and skin grafting.
o5 participants (3.9%) had secondary lesions, and 15 participants (11.6%) had functional limitations.
Abbreviations: Lab, laboratory confirmation; NR, not reported; Osteo, osteomyelitis; POS, prospective observational study; RCT,
randomized controlled trial; RFP, rifampicin; Rx, treatment; SM, streptomycin.
Table 3. Rifampicin combined with clarithromycin for treating Buruli ulcer: description of studies and main results
Regi-
men
Study De-
sign
Com-
par-
isons
Surgery
Inclu-
sion
(age,
le-
sion)
Labo-
ratory
(Y/N)
N Sex
(M:F)
Age Le-
sion
types
Ques-
tion
Out-
come
mea-
sure
and
time
point
(num-
ber if
dif-
ferent
from
N)
Re-
sults
Our
obser-
vation
RFP
and
CAM
Chauty
2011
POS 1
group:
Rx
given
for 8
weeks
When
indi-
cated
≥ 5
years
Size ≤
10 cm
Y 30 18:12 NR Ul-
cer: 21
(70%)
Non-
ul-
cer: 9
(30%)
Does 8
weeks
of RFP
+
CAM
work?
Healed
with
Rx ±
surgery,
12
months
30/30
(100%)
Regi-
men
com-
bined
with
surgery
as
needed
was
asso-
ciated
with
high
heal-
ing
rate
at 12
months
and no
recur-
rence
at 18
months
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Table 3. Rifampicin combined with clarithromycin for treating Buruli ulcer: description of studies and main results (Con-
tinued)
in
partic-
ipants
with
small
le-
sions.
50%
of
partic-
ipants
healed
with
Rx
alone.
50%
re-
quired
surgery
to heal
Healed
with
Rx
alone,
12
months
15/30
(50%)
a
Un-
der-
went
surgery,
12
months
15/30
(50%)
Healed
with
Rx +
surgery,
12
months
(n =
15)
15/15
(100%)
b
Recur-
rence,
18
months
None
RFP
and
CAM
O’Brien
2012
POS 1
group:
Rx,
dura-
tion
de-
pend-
ing
upon
physi-
All None Y 21 NR NR NR Does
RFP +
CAM
plus
surgery
work?
Healed
with
Rx +
surgery,
12
months
21/21
(100%) Surgery
plus
Rx was
asso-
ciated
with
high
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Table 3. Rifampicin combined with clarithromycin for treating Buruli ulcer: description of studies and main results (Con-
tinued)
cian’s
deci-
sion
heal-
ing
rate
and no
recur-
rence
at 12
months.
Inde-
pen-
dent
effect
of
antibi-
otics
not
evalu-
ated.
Dura-
tion
of Rx
varied
Recur-
rence ,
12
months
None
RFP
and
SM
plus
RFP
and
CAM
BU-
RULICO
Study
2010
RCT 2
groups:
1. RFP +
SM
for 4
weeks
(4RS)
fol-
lowed
by
RFP +
CAM
for 4
weeks
(4RC)
2. RS for
8
weeks
(8RS)
When
indi-
cated
≥ 5
years
Size ≤
10 cm
Y 151 46:
105 1. Median
12
years
(IQR
9 to
22)
2. Median
12
years
(IQR
8 to
18)
Ul-
cer: 59
(39%)
Non-
ul-
cer: 92
(61%)
Can
RFP +
CAM
substi-
tute
for
RFP +
SM?
Healed
with
Rx
alone
or Rx
+ skin
graft-
ing,
12
months
1. 68/75
(91%)
2. 73/76
(96%)
c,d
4RS +
4RC
was as
effec-
tive as
8RS in
partic-
ipants
with
small
le-
sions.
Both
regi-
mens
were
asso-
ciated
with
high
heal-
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Table 3. Rifampicin combined with clarithromycin for treating Buruli ulcer: description of studies and main results (Con-
tinued)
ing
rate
and no
recur-
rence
at 12
months
Differ-
ence in
heal-
ing
time
Nonee
Recur-
rence,
12
months
None
RFP
and
SM
plus
RFP
and
CAM
Phillips
2014a
POS 1
group:
RFP
+ SM
for 2
weeks
(2RS)
fol-
lowed
by
RFP +
CAM
for 6
weeks
(6RC)
When
indi-
cated
≥ 5
years
Size ≤
15 cm
Y 43 18:25 Me-
dian
14
years
(5 to
70)
Ul-
cer: 20
(47%)
Nod-
ules:
14
(32%)
Plaque:
9
(21%)
Can
RFP +
CAM
substi-
tute
for
RFP +
SM?
Healed
with
Rx ±
surgery,
12
months
(n =
41)f
41/41
(100%)
2RS +
6RC
com-
bined
with
surgery
as
needed
was
asso-
ciated
with
high
heal-
ing
and
low
recur-
rence
at 12
months
in
partic-
ipants
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Table 3. Rifampicin combined with clarithromycin for treating Buruli ulcer: description of studies and main results (Con-
tinued)
with
small
le-
sions.
98%
of
partic-
ipants
healed
with
Rx
alone.
2RS +
6RC
may
sub-
stitute
for
8RS,
but no
defini-
tive
con-
clu-
sion
could
be
made
as they
were
not
com-
pared
Healed
with
Rx
alone,
12
months
(n =
41)f
40/41
(98%)
Un-
der-
went
surgery
(n =
41)f
1/
41 (2.
4%)
Healed
with
Rx +
surgery,
12
months
(n = 1)
1/1
(100%)
g
Recur-
rence,
12
months
(n =
41)f
None
a8/10 (80%) with ulcerative-WHO category I lesion; 5/11 (45%) with ulcerative-WHO category II lesion; 2/3 (66%) with non-
ulcerative-WHO category I lesion; 0/6 (0%) with non-ulcerative-WHO category II lesion.
b11 (37%) with limited surgery; 4 (13%) with excision and skin grafting.
cSkin grafting without excision: (1) 1/75 (1.3%); (2) 4/76 (5.3%).
dOdds ratio 2.49, 95% confidence interval 0.66 to infinity; P = 0.16, 1-sided Fisher’s exact test.
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eGroup proportional hazard model: P = 0.26; 99% confidence interval 0.22 to 0.29; generalized Wilcoxon-Mann-Whitney test: P =
0.60; 99% confidence interval 0.56 to 0.64.
f 2 lost to follow-up.
gSkin grafting at week 32.
Abbreviations: CAM, clarithromycin; IQR, interquartile range; Lab, laboratory confirmation; NR, not reported; POS, prospective
observational study; RCT, randomized controlled trial; RFP, rifampicin; Rx, treatment; SM, streptomycin.
Table 4. Novel combination regimens for treating Buruli ulcer: description of studies and main results
Regi-
men
Study De-
sign
Com-
pari-
son(s)
Surgery
Inclu-
sion
(age,
le-
sion)
Labo-
ratory
(Y/N)
N Sex
(M:F)
Age Le-
sion
types
Ques-
tion
Out-
come
mea-
sure
and
time
point
(num-
ber if
dif-
ferent
from
N)
Re-
sults
Our
obser-
vation
RFP
and
DDS
Espey
2002
RCT 2
groups:
1. Rx for
8
weeks
(n =
15)
2. Placebo
(n =
15)
None > 4
years
Ulcer
N 30 18:12 NR Ulcer:
30
(100%)
Is RFP
+
DDS
effec-
tive?
Im-
proved
after 2
months
(n =
28)a
1. 82%
(23/
28
points)
2. 75%
(21/
28
points)
b
Un-
able to
assess
the
effect
due to
incon-
gruent
char-
acter-
istics
at
base-
line,
how-
ever
there
seems
to be
no ob-
vious
effect
Change
in
1. 14.0
cm2
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Table 4. Novel combination regimens for treating Buruli ulcer: description of studies and main results (Continued)
ulcer
size
after 2
months
de-
crease
(range,
3.8 to
-159.
0)
2. 2.5
cm2
de-
crease
(range,
78.0
to -
35.0)c
RFP
and
either
CIPRO,
CAM,
or
MOX
Fried-
man
2016
POS 3
groups:
1. RFP +
CIPRO
(n =
80)
2. RFP +
CAM
(n =
50)
3. RFP +
MOX
(n =
2)
Lim-
ited
surgi-
cal de-
bride-
ment
when
indi-
catedd
(ex-
ten-
sive
sur-
gical
exci-
sions
ex-
cluded)
None Y 132 75:57 Me-
dian
49
years
(1 to
95)
Ulcer:
110
(83.
3%)
Nod-
ule: 9
(6.
8%)
Oedema:
10 (7.
6%)
Plaque:
3 (2.
3%)
Does
RFP-
based
all-
oral
Rx
regi-
men
work?
Healed
with
Rx ±
lim-
ited
surgi-
cal de-
bride-
ment,
12
months
131/
132
(99%)
e
RFP-
based
all-
oral
regi-
mens
com-
bined
with
lim-
ited
surgi-
cal de-
bride-
ment
as
needed
were
asso-
ciated
with
high
heal-
ing
rate
and
no
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Table 4. Novel combination regimens for treating Buruli ulcer: description of studies and main results (Continued)
recur-
rence
at 12
months.
77%
of
partic-
ipants
healed
with
Rx
alone.
Some
lesions
may
need
less
than 8
weeks
of
Rx to
achieve
heal-
ing.
These
were
less
severe
pa-
tients,
as pa-
tients
who
re-
quired
exten-
sive
surgi-
cal ex-
cision
were
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Table 4. Novel combination regimens for treating Buruli ulcer: description of studies and main results (Continued)
ex-
cluded.
No
inde-
pen-
dent
results
were
given
for
dif-
ferent
regi-
mens
Healed
with
Rx
alone,
12
months
101/
132
(76.
5%)
Me-
dian
dura-
tion of
ther-
apy
56
days
(IQR
24 to
96
days)
Dura-
tion of
ther-
apy: <
8
weeks
22/
132
(16.
7%)
Re-
cur-
rence,
12
months
None
Com-
bina-
tion of
RFP,
CIPRO,
CAM,
ETB,
MOX,
O’Brien
2012
POS 2
groups:
1. All-
oral
Rx (8
differ-
All None Y 133f 67:66 Me-
dian
62
years
(3 to
94)
Ulcer:
106
(87%)
Nod-
ules: 9
(7%)
Is all-
oral
Rx
treat-
ment
plus
Healed,
12
months
g
1. 90/90
(100%)
2. 33/47
(70%)
The
tested
all-
oral
regi-
men
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Table 4. Novel combination regimens for treating Buruli ulcer: description of studies and main results (Continued)
AMK ent
regi-
mens:
see be-
low) +
surgery
2. Surgery
alone
Regi-
mens:
1. RFP +
CIPRO
(n =
55)
2. RFP +
CAM
(n =
21)
3. RFP +
CAM
+
ETB
(n =
5)
4. CIPRO
+
CAM
(n =
4)
5. RFP +
MOX
(n =
2)
6. CAM
+
ETB
(n =
1)
7. RFP +
Oedema:
7
(6%)f
surgery
supe-
rior
to just
surgery?
h plus
surgery
was
asso-
ciated
with
100%
heal-
ing
and
no
recur-
rence
at 12
months.
30%
of
partic-
ipants
who
only
had
surgery
had
recur-
rence.
Indi-
vidual
effect
of Rx
not
evalu-
ated
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Table 4. Novel combination regimens for treating Buruli ulcer: description of studies and main results (Continued)
ETB
+
AMK
(n =
1)
8. CAM
(n =
1)
Re-
cur-
rence,
12
months
g
1. 0/90
(0%)
2. 14/47
(30%)
i
aJudged by 2 Buruli ulcer specialists using photographs taken at enrolment and at 2 months. Photographs were available for 14
participants from each group; each evaluator’s score was counted as 1 point.
bP = 0.51.
cP = 0.02; however, the initial median ulcer size was bigger in the treatment group than in the placebo group (26.2 cm2 (0.25 to 280)
versus 4.8 cm2 (0.25 to 57.5), P = 0.04).
dLimited surgical debridement was defined as curettage of the lesion or a minor excision to remove excess granulation tissue and to
debride ulcer margins, with or without the use of a split skin graft.
eResults not available for each individual regimen.
fClinical type of lesion was recorded in 122/133 participants (92%).
g137 lesions were analysed.
hP < 0.001.
iMedian time of recurrence: 90 days (range, 14 to 300 days).
Abbreviations: AMK, amikacin; DDS, dapsone; CAM, clarithromycin; CIPRO, ciprofloxacin; ETB, ethambutol; IQR, interquartile
range; Lab, laboratory confirmation; MOX, moxifloxacin; NR, not reported; POS, prospective observational study; RCT, randomized
controlled trial; RFP, rifampicin; Rx, treatment; SM, streptomycin.
Table 5. Paradoxical reactions in Buruli ulcer: description of studies and main results
Regi-
men
Study Design Com-
parisons
Surgery N Sex
(M:F)
Age Lesion
types
Inci-
dence of
PR
On-
set time
of PR
Our ob-
serva-
tion
RFP and
SM
Sarfo
2010
POS 1 group:
RFP
+ SM for
8 weeks
(8RS)
When
indi-
cated
(post-
Rx)
160 66:94 Median
12 years
(1 to 75)
Ulcer: 86
(54%)
Nodule:
36 (22%)
Plaque:
14 (9%)
Oedema:
24 (15%)
3/159 (1.
9%)a
At weeks
4, 6, 12
Approx-
imately 1
in 20 par-
ticipants
treated
with 8RS
devel-
oped PR.
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Table 5. Paradoxical reactions in Buruli ulcer: description of studies and main results (Continued)
2 cases
occurred
during
Rx and 1
case
occurred
post-Rx
RFP and
SM
or
RFP and
SM
plus
RFP and
CAM
Barogui
2016
POS 1 group:
1. RFP +
SM for 8
weeks (n
= 166)
2. RFP +
SM for
4 weeks
followed
by RFP
+ CAM
for 4
weeks (n
= 75)
When
indi-
cated
241 88:153 Mean
(SD) 16
(13) years
Ul-
cer: 108
(45%)
Nodule:
32 (13%)
Plaque:
56 (23%)
Oedema:
11 (5%)
Mixed:
34 (14%)
52/241
(22%)b
Between
week 8
and 12
Approx-
imately 1
in 5 par-
ticipants
treated
with
Rx devel-
oped PR
between
week 8
and 12
RFP and
SM
plus
RFP and
CAM
Phillips
2014a
POS 1 group:
RFP
+ SM for
2 weeks
(2RS)
followed
by RFP
+ CAM
for
6 weeks
(6RC)
When
indi-
cated
43 18:25 Median
14 years
(5 to 70)
Ulcer: 20
(47%)
Nodules:
14 (32%)
Plaque: 9
(21%)
4/41 (9.
3%)c
Median
12 weeks
(range, 4
to 32
weeks)
Approx-
imately 1
in 10 par-
ticipants
treated
with 2RS
+
6RC de-
veloped
PR atme-
dian
12 weeks
after start
of treat-
ment
Combi-
nation
of RFP,
CIPRO,
CAM,
ETB,
AMK,
MOX
O’Brien
2012
POS 8
groups:
Weeks of
1. RFP +
CIPRO
(n = 55)
All 90 NR NR NR 8/90 (8.
9%)d
Median
48 days
(range,
14 to 85
days)
Approx-
imately 1
in 10 par-
ticipants
treated
with dif-
fer-
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2. RFP +
CAM (n
= 21)
3. RFP +
CAM +
ETB (n
= 5)
4. CIPRO
+ CAM
(n = 4)
5. RFP +
MOX (n
= 2)
6. CAM +
ETB (n
= 1)
7. RFP +
ETB +
AMK (n
= 1)
8. CAM (n
= 1)
ent regi-
mens of
Rx devel-
oped PR
at
median 8
weeks
after start
of treat-
ment
Combi-
nation
of RFP,
CAM,
ETB,
AMK,
MOX
O’Brien
2013b
POS 1 group:
received
Rx
When
indi-
cated
156 86:70 < 15
years: 13
(8%);
15 to 60
years: 62
(40%);
> 60
years: 81
(52%)
Ulcer:
137 (87.
8%)
Nodules:
10 (6.
4%)
Oedema:
9 (5.8%)
32/156
(21%)e
Median
39 days
(IQR
20 to 73
days)
Approx-
imately 1
in 5 par-
ticipants
treated
with dif-
fer-
ent regi-
mens of
Rx devel-
oped PR
at
5.6 weeks
after start
of treat-
ment
RFP and
either
CIPRO,
CAM,
Fried-
man
2016
POS 3
groups:
Weeks of
Lim-
ited sur-
gical de-
132 75:57 Median
49 years
(1 to 95)
Ulcer:
110 (83.
3%)
34/132
(26%)d
Median
48 days
(IQR
Approx-
imately 1
in 4 par-
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Table 5. Paradoxical reactions in Buruli ulcer: description of studies and main results (Continued)
or MOX
1. RFP +
CIPRO
(n = 80)
2. RFP +
CAM (n
= 50)
3. RFP +
MOX (n
= 2)
bride-
ment
when in-
dicated
Nodule:
9 (6.8%)
Oedema:
10 (7.
6%)
Plaque: 3
(2.3%)
29 to 69
days)
ticipants
treated
with dif-
fer-
ent regi-
mens of
Rx devel-
oped PR
at
median 8
weeks
after start
of treat-
ment
aOne death.
b37/166 (22%) received RFP + CIPRO; 15/75 (20%) received RFP + CAM.
c2 participants lost to follow-up.
dResults not available for each individual regimen.
ePredictors of paradoxical reactions (multivariable analysis): age ≥ 60 years (risk ratio (RR) 2.84, 95% confidence interval (CI) 1.12
to 7.17; P = 0.03), oedematous lesion (RR 3.44, 95% CI 1.11 to 10.70; P = 0.03), use of amikacin in the initial Rx regimen (RR 6.33,
95% CI 2.09 to 19.18; P < 0.01).
Abbreviations: AMK, amikacin; CAM, clarithromycin; CIPRO, ciprofloxacin; ETB, ethambutol; IQR, interquartile range; Lab, lab-
oratory confirmation; MOX, moxifloxacin; NR, not reported; POS, prospective observational study; PR, paradoxical reactions; RCT,
randomized controlled trial; RFP, rifampicin; Rx, treatment; SD, standard deviation; SM, streptomycin.
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We did not include the planned methods for conducting meta-analyses in the review due to the small number of included studies and
their heterogeneity.
We added paradoxical reactions to the Secondary outcomes.
We revised the ‘Risk of bias’ assessment. The method stated in the protocol was only applicable to randomized controlled trials and
not to prospective observational studies.
We added the following search terms: ‘Buruli and skin’, ‘mycobacterial skin ulcer*’, and ‘mycobacterium skin ulcer*’.
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